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Please find the attached proposal and preliminary design for the Monoclonal Antibody 
Biopharmaceutical Manufacturing Facility. This proposal provides a detailed preliminary design 
of the seed train, production reactor, purification processes, storage, waste treatment, clean in 
place, steam in place, and water for injection production. The team was able to optimize the 
manufacturing process such that it produced 1500 kg of mAb per year at a titer of 2 g/L while 
still meeting the other requirements and specifications set out in the problem statement. Over the 
25 year project life, the process has a NPV of $31.4 billion and a DCFROR of 6350%. 
 
The team strongly recommends that AICHE proceeds with the investment and construction of 
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 The objective of this preliminary design was to determine the technical and economic 
feasibility of constructing a biopharmaceutical production facility to produce humanized 
monoclonal antibodies from Chinese Hamster Ovary cells. The mAb production facility will need 
to produce a minimum of 1,000 kg of product a year at current titers of 1-2 g/L of mAb as well 
as at future titers of 5-10 g/L. 
 
The team performed the preliminary design of the production facility based on the mAb 
production block flow diagram provided by The Company’s management as well as the physical 
specifications of the CHO cell line. The final optimized design includes a seed train process to 
promote controlled cell culture growth, two mAb production bioreactors, a protein harvesting 
and downstream purification process, frozen storage, and a waste inactivation process. One of 
the major considerations taken by the design team was the sterile nature of the process. In 
order to provide a sterile environment for each step in the process, a water for injection 
production process was designed, as well as a comprehensive steam in place and clean in place 
system. The process designed proves technical feasibility of the project in meeting physical, 
safety, and health specifications. 
 
The facility is estimated to require 44 operating personnel working at any given time in order to 
ensure safe operation. As a batch process, raw material handling presents both a safety hazard 
and biohazard. In order to mitigate either of these concerns, viral inactivation and assays are 
performed throughout the process, and storage of caustic and acidic buffers is minimized. 
 
The economic analysis performed for the process proves that the project is economically 
attractive. A summary of the major economic parameters over the 25-year project life is 
provided in Table 1 below. 
 




The economic parameters show that the project’s economic results far exceed the 
requirements for the project to be economically successful.  The team suggests that The 







Antibodies are Y-shaped proteins produced by animal and human immune systems when they 
are attacked by viruses, bacteria, and other harmful pathogens. These proteins attach to the 
antigens on the targeted cell, marking them for white blood cells to attack [1]. This process of 
antigen-antibody binding is shown in Figure 1. 
 
Antibodies produced in a lab or pharmaceutical 
manufacturing facility and grown from a single cell 
line are known as monoclonal antibodies (mAbs) 
[1]. There are several different types of 
monoclonal antibodies. Naked mAbs latch onto the 
antigen without any drugs or materials attached to 
them. They are the most common type of mAb in 
cancer treatments. Conjugated mAbs are 
combined with radioactive particles that attach to 
the targeted antigen. Lastly, there are bispecific 
mAbs. These drugs are made of two different mAb 
proteins that target two different types of antigens 
[1].  
 
MAb cells have three main applications: diagnostics, 
therapeutic, and protein purification [3]. Examples 
of how these applications are applied are shown in Table 2.  For example, when used to battle 
cancer, mAbs are a type of immunotherapy [2]. MAbs like, vascular endothelial growth factor 
(VEGF), are used to attack types of cancers of vascular endothelial cells.  
  Table 2 : Applications of mAb [3] 
Figure 1 : MAb antibody attaching to 






In biopharmaceutical production, host cells are needed to use the recombinant DNA to create 
new genetic combinations and therapeutic proteins [4]. The most commonly chosen host is 
Chinese hamster ovary cells (CHO) as they are the current mammalian platform. CHO cells are 
also desirable because they have more benefits than not which are down in Table 3. CHO cells 
make up more than half of the therapeutic protein market. The market is worth over $140 
billion per year [4]. 
 
Table 3: Pros and Cons of CHO cells [5] 
Pros Cons 
High viability, rapid growth, easy to culture, high 
expression levels, low cost 




Monoclonal antibodies are primarily used in hospitals and research facilities as they are also 
widely accepted by biologics [4]. Over 35% of the hospital mAb end-use is for cancer treatments 
[6]. MAbs are used to fight a variety of cancers as shown in Figure 2. A key contributor to 
predicted mAb market growth is an increase in use for treatment of chronic conditions, 
healthcare coverage, and public awareness of mAb treatments.  
 
Chimeric mAbs are derived from murine sources and their genetic sequence is only 70% human. 
The cell lines that generate human mAbs produce low titers and can be unstable. Humanized 
mAbs, like the antibodies produced from CHO cells have 95% of the human sequence. They are 
ideal because the non-human portion is where the antigen binding regions are. For this reason, 
the market for humanized mAbs is growing more rapidly than the other types as shown in 
Figure 3.  
Figure 2: Breakdown of Mab cancer 
applications in 2016 [4] 
 






Much like many pharmaceutical manufacturers, The Company is trying to break into the mAb 
market. The Company has already received approval for at least one mAb product and has others 
that are currently in development. Due to momentum surrounding mAbs and associated 
biopharmaceuticals both within The Company and the larger medical community, the 
manufacturing branch of the company has been charged with designing a large-scale mAb 
manufacturing facility that can produce enough product to handle a full-scale commercial 
launch. The potential facility will be located next to the current ‘Research and Development’ 
building to capitalize on preexisting infrastructure. There is potential for the site to become a 
contract manufacturing facility in the future if the initial launch goes well. Therefore, the design 
needs to be flexible to allow for the production of a variety of mAbs at a variety of purities and 
for a variety of purposes. The site should be able to produce a minimum of 1000 kg of purified 
mAbs per year at titers ranging from 1-2 g/L to 5-10 g/L. The production facility should 
encompass the seed train, upstream (production), downstream (purification), packaging, and 
storage processes. From this facility, mAb products will be sent to another facility for final 
formulation and distribution. Since this is a completely new facility, every part of the process 
will need to be designed from the ground up—everything that is needed in the process must be 
accounted for in the design. Although the process should be able to accommodate a variety of 
mAb products, for the sake of this design, it is assumed that the production will be a VEGF 
antibody similar to Avastin ™. This report contains Global Manufacturing’s mAb 
biopharmaceutical manufacturing facility design, economic analysis, and recommendations that 
the management of The Company has requested. 
PROCESS FLOW DIAGRAM  
 
Table 4: Equipment Identification Key 
 
 























MATERIAL AND ENERGY BALANCES 
 
One of the most important aspects of a preliminary design is its technical feasibility. On the 
most basic level, mass and energy must balance throughout the entire process for the technical 
validity of the process to be verified. Table 5 below summarizes the pressure, temperature, 
mass flow, and enthalpy for each stream in the mAb production process, allowing for 



























Figure 5: Process Block Flow Diagram 
Design Basis 
The scope of this project was to design a facility that produced a minimum of 1000 kg of mAb 
per year. The block diagram (Figure 6) above, gives an overview of the entire process. The seed 
train must be inoculated from one 1 mL vial holding 1 x106 CHO cells, with only one vial used 
per batch. The doubling time for CHO cells was estimated to be 36 hours. Each step in the seed 
train was operated in a batch manner and was performed under sterile conditions. The cell 
culturing media was required to be a powdered, chemically-defined, serum-free media that was 
mixed into solution on site. The production bioreactor was designed to produce a minimum 
mAb titer (concentration per batch) of 1-2 g/L with the expectation that the titer could be 
increased to 5-10 g/L in the future. The production reactor could be operated in either a batch 
or a fed-batch manner. Throughout this final production step, the concentration of glucose in 
the reactor had to be maintained above 2 g/L. Per the project guidelines, it was assumed that 
each CHO cell produces 25 pg of mAb per day during both the seed train and bioreactor 
















The product leaving the seed train and bioreactors must be sanitized and purified to the 
standards set forth by the FDA for pharmaceutical processes [7]. The most significant of these 
regulations include having two purification steps that inactivate any biological contaminants 
including viruses. After the purification and viral inactivation steps, the final product was 
required to be packaged and stably stored for up to one year. Other considerations due to the 
sterile nature of the process include SIP (steam in place) and CIP (clean in place) of process 
vessels in between batches and the use of WFI (water for injection) as opposed to potable 
water in the process. The option was given in the project guidelines of purchasing WFI for $1/L 
or of purchasing potable water for $0.543/1000 L and purifying this water to meet the USP 
(United States Pharmacopeia) guidelines for WFI. Waste from the process was to be pretreated 
and disposed of using the existing city sewage system at the cost of $5/1000 gal. Existing 
electricity utility is also provided at the site, for a current rate of $0.05/kW-hr. The on-site 
utilities provided to the project team are summarized below in Table 7. 
 
Table 7: Cost of On-Site Utilities 
 
  
Not all parameters necessary to evaluate the project were provided by management, so some 
assumptions were made by the project evaluation and preliminary design team. These project 
assumptions are summarized in Table 8 below. 
 







The two main factors that influenced the design of this process were the minimum mAb 
production rate (1000 kg/yr) and the sterile nature of the process. The production rate 
determined the way that the upstream process was designed—both the amount of mAb 
produced in each batch and the number of batches per year were maximized to at least hit the 
minimum mAb production. The production rate was always the first and foremost priority in 
the design, and everything else was based upon meeting it. In regards to the mAb titer in the 
production reactor, this design is based solely on the current titer of 1-2 g/L. The optimization 
of the process production centered around increasing total mAb production in the process 
(minimum of 1000 kg/yr) rather than increasing the concentration of mAb in the product 
reactor (1-2 g/L). Potential ways that this design could be used to produce a larger titer of mAb 
will are addressed in the Process Scale Up subsection. The other main factor in the design was 
maintaining a sterile environment and dealing with the biological hazard both within and 
without the process properly. A large portion of the design is devoted to a water for 
injection/steam in place (SIP) system and a clean in place (CIP) system, both of which are 
necessary for keeping a biopharmaceutical manufacturing process sterile. Other important 
pieces of the design that were emphasized because of the sterile nature of the product are the 
viral inactivation steps and the waste treatment and disposal process. The following are 
examples of ways that the process was optimized in order to properly account for these two 
main factors. 
 
Seed Train Densities 
One of the keys to properly designing the seed train is managing the different phases of cell 
growth. For this design, much attention was given to selecting an optimum media for CHO 
growth and understanding how the media affected cell growth. The media that was selected for 
this process was BalanCD CHO Growth A media. This media was proven to be an optimal media 
for CHO production because of the length of time that cells remained viable in it [8]. In fact, 
cultures remained viable and growing in densities of up to 9 million cells/mL of media, a larger 
number than most other CHO media can support [8]. Knowing this about the media, the team 
designed the seed train to keep cells in each vessel as long as the log phase was continuing, and 
to remove the cells before they reached maximum density. It was established that the cells 
would be inoculated at 2x105 cells/mL and harvested at 4x106, a lower density than the 
maximum. Working within this range of densities allows the process to produce the required 
number of cells to produce the minimum amount of mAb per year.  
 
Scheduling Optimization 
Besides optimizing the cell culturing process, the second most important way to maximize 
production is by optimizing the scheduling of the process. Although each step in this process is 
batch, the steps can be scheduled in such a way as to maximize efficiency by minimizing the lag 
time between each step. One way that scheduling was used to optimize the process was by 
operating some of the downstream process steps in cycles. The centrifuge and first two 
chromatography columns processed only a portion of the product stream at a time, decreasing 




process was optimized was by debottlenecking it so that the cycle time, or time between 
batches could be decreased, increasing the number of batches per year. Once the original 
process was designed with the minimum, necessary pieces of equipment, the schedule was 
examined to see where the bottleneck in the process was. Figure 6 below is the equipment 
occupancy chart for the first 100 days of the original design. As is made clear by the chart, 
bioreactor R-301 is the bottleneck in the process. The minimum possible time between batches 
(cycle time) is 12 days, limiting the facility to just under 30 batches per year. With a production 
amount of 29.6 g/batch, this design won’t meet the minimum mAb production requirement. To 
optimize this process, a second (and identical) R-301 bioreactor was added to the process. The 
operation of the two bioreactors is staggered, so that the reactors take turns being used in the 
process. The same equipment occupancy chart with a second R-301 bioreactor is displayed 
below in Figure 7. In the chart, R-301 a/b is the original reactor and STG01 is the second 
reactor. Adding a second R-301 reactor reduces the cycle time to 7 days, allowing the facility to 
process 51 batches and produce over 1500 kg of mAb each year. This optimized design is the 
one that was chosen for the rest of the process because it greatly increased the yearly 
production of mAb while only increasing the capital cost by a small amount. 
 
 






Figure 7: Equipment occupancy chart with cycle time optimization 
 
Water for Injection 
As specified in the project statement and made very clear in FDA and USP regulations, all water 
that is used in the process that in any way comes into contact with the product streams is 
required to be water for injection [9] Water for injection (WFI) is available for purchase for 
$1000/1000 L, however the cost of purchasing that much water adds up quickly when 
considering that one batch of mAb production requires nearly 130,000 L of water for injection, 
as well as another 25,000 kg of clean steam needed for steam in place (SIP) of process 
equipment. Purchasing that much water greatly increases the operating cost of the process. To 
make the process more cost-effective, a water for injection skid was designed that purifies 
potable water until it is up to the USP standard for WFI [10,11]The skid was designed so that it 
could handle potable water and even relatively “clean” waste streams from the process such as 
the diafiltration flush outlet stream. In order to realistically simulate the process, a water 
stream was designed using the maximum allowable contaminants in potable water per the EPA 
regulation [12]. The contaminants added to the water are listed in Table 9 below. Although 
there are more contaminants in potable water than those listed, these represent the variety of 
possible contaminants in water. Some of the contaminants listed, such as sodium, are not 
regulated by the EPA but were listed on the Boston, MA municipal water report [13]. Since 
much of the pharmaceutical industry is located in the Boson-Cambridge area, this water was 









Table 9 – Potable Water Estimated Contaminants Concentration 
 
 
In the Economic Analysis – Optimization Analysis Section of the report, the designed WFI 
system is compared to buying the necessary WFI from an economics standpoint. It is estimated 
that the operating cost of producing WFI is $3-5/1000 L [15], which if true would make 
producing WFI a very attractive option. Some of the non-economic benefits of designing a WFI 
system is that it allows the manufacturing process to control the volume of WFI that is 
produced and stored at any one time. If WFI is purchased, the process is dependent upon the 
supply of another raw material instead of on a process that can be continuously run to produce 
more of the needed material.  
 
Heat Integration 
Another optimization step performed in the process is utilizing heat integration, both within the 
WFI system and the overall process. One example is using municipal water to cool down the 
bioreactors and then sending that same potable water to the WFI system to be processed into 
WFI. Combining these streams allows for the better utilization of resources and greatly reduces 
the amount of water bought only for cooling. In the WFI system, the purified water stream is 
pre-heated by exchanging heat with the hot water stream drained from the boiler and the WFI 
saturated steam. Next, the pre-heated purified water is boiled in the steam boiler by an electric 
coil and a steam coil fueled by the steam leaving the boiler and subsequent compressor. 
Integrating these heat streams allows WFI and Clean Steam to be produced and cooled to their 
respective correct states for a total of 306 kW. Finally, the compressed air that is supplied to 
the bioreactors is cooled to 37 C, the reactor temperature, by potable water that is then 
supplied to the WFI system. This integration of heat minimizes operating costs while also 
making good use of thermal energy conservation within the process.  
 
Compressed Air 
The final optimization step considered in the design of the process was compressing air for the 
bioreactors rather than buying compressed air. Over the course of one batch, 406.8 m3 of air 
are fed into the three bioreactors in the process to maintain a constant oxygen concentration in 
the culture media. Compressed air is available in industrial sized cylinders with sizes up to 
10,000 L per cylinder [16]. The issue with buying compressed air for this process is that one 
batch of would use 41 of these cylinders or almost 6 canisters per day. The required storage 
space and man power to use these canisters outweighs the ease of designing a compression 
skid that continuously filters, compresses, and cools the air for the reactor. The decision to 
design this skid, although not economically motivated, optimizes the functionality of the 






The process begins with cell culture media preparation. The serum-free media, BalanCD CHO 
Growth A Media, is mixed immediately prior to each new inoculation. For every L of media 
solution prepared, 23.1 g and 2.09 g of Growth A media and sodium bicarbonate are added 
respectively [17]. The first four steps of the seed train, t-flasks (TF-201) through cell bag 
bioreactor (CB-206), are inoculated with media that is prepared in sterile glassware in a sterile 
room. The glassware is sterilized in an autoclave after each use. Media for both seed train 
bioreactors, R-207 and R-208, is prepared in Media Prep Vessel 1, V-101, and is pumped into 
the seed train bioreactors using Media Prep Pump 1, P-102. Media Prep Vessel 1 is connected 
directly to the WFI system; media powder and sodium bicarbonate are manually added to the 
vessel. Using an impeller, the media ingredients are well-mixed to produce the inoculation 
solution. The amounts of media added to R-207 and R-208 for each batch is 165 L and 3325 L 
respectively. The inoculation media for the Production Bioreactor, R-301 A/B, is prepared in 
Media Prep Vessel 2, V-103, using the same method explained above. For each batch, 16,500 L 
of Growth A media solution will be pumped to R-301 using Media Prep Pump 2, P-104. The 
Production Bioreactor is operated as a fed-batch process, with BalanCD CHO Feed 4 media 
solution being added over the course of the reaction. The amounts of Feed 4 media powder 
and sodium bicarbonate added per L of solution are 107.45 g and 2.09 g respectively [17] The 
feed media is prepared in Feed Media Prep Vessel, V-105 A/B, using the same method 
explained above. The media fromV-105 A/B will be fed to R-301 A/B through Feed Media Pump, 
P-106. In order to minimize the time in between batches, two identical Production Bioreactors, 
R-301 A/B, were designed, each with its own Feed Media Prep Vessel, V-105 A/B, but sharing a 
Media Prep Vessel, V-103, and pumps P-104 and P-106. 
 
Seed Train  
The seed trains consists of a series of cell culture containers, each larger than the last, for the 
purpose of multiplying the number of cells from the cell source. A large number of cells is 
required to produce more mAbs, therefore the seed train is designed to maximize the number 
of cells entering the production bioreactor. The seed train begins by adding 5 mL of Growth A 
media solution to T-Flask 1, TF-201, thereby preparing it for inoculation. Next one 1 mL vial 
containing one million CHO cells is inoculated into TF-201. The CHO cells are incubated in T-
Flask 1 for 3.5 days. After the allotted time has ended, the approximately 5x106 cells are 
inoculated into TF-202 which contains 20 mL of inoculation solution. The cells are incubated in 
TF-202 for 6.5 days. Next the 1x108 cells are inoculated in the Roller Bottle, RB-204, with an 
additional 475 mL of inoculation solution and incubated for 6.5 days. During incubation, the 
solution is constantly agitated as the Roller Bottle Roller, RB-203, keeps RB-204 in constant 
radial motion. This agitation keeps the cells in suspension and promotes good dispersion of 
nutrients throughout the media. Next the cells, now approximately 2x109, are inoculated in Cell 
Bag Bioreactor, CB-206, with an addition of 9.5 L of Growth A media solution. The culture is 
agitated by Cell Bag Rocker, CB-205, through a continuous rocking motion during the 6.2 days 
of incubation time. During these steps of the seed train, the inoculation vessels and media 





From CB-205, the 3.5x1010 cells in the culture are inoculated in a Seed Culture Bioreactor 1, R-
207. The reactor is filled with 165 L of Growth A solution from V-101 by P-102 prior to 
inoculation. This cell culture is allowed to incubate for 6.5 days. During this time, R-207 is 
supplied with .25 m3/min by Air Compressor, C-211, that helps to agitate the cells and 
maintains an adequate oxygen concentration in the solution for optimal cell growth. A vent is 
located on the reactor to allow excess carbon dioxide produced by the cells and inert nitrogen 
to leave the reactor. Using the vent, the pressure in the vessel is maintained at 1.013 bara. The 
cells in R-207 are additionally agitated by a low rpm impeller. After the 6.5 days are over, the 
7x1011 cell culture is moved to the final seed train step, Seed Culture Bioreactor 2, R-208. R-208 
is prepared with 3,325 L of Growth A media solution through the use of V-101 and P-102. The 
culture incubates for 6.5 days and is fed a constant supply of air throughout by C-211. 
Additionally, this reactor contains the same impeller and vent systems mentioned above for R-
207. The air entering C-211 is first filtered through Air Cartridge Filter, F-210, before being 
compressed from 1.013 bara to 1.7 bara. This compression also raises the temperature of the 
ambient air from 25 to 89°C, so the air is cooled back to 37°C by Air Compressor After-Cooler, 
HE-212 using 3250 L/hr of cooling water. The reactors are maintained at 37°C through 11.4 and 
243 kg/hr of cooling water flowing through their respective jackets (R-207 and R-208). After 
cooling off the reactors, this water is fed to the WFI system as potable feed water. 
 
Production Bioreactors 
From R-208, the 1.4x1013 culture is inoculated in the Production Bioreactor, R-301 A/B. 
Although each step in the seed train process has produced mAbs, the large number of cells in 
this reactor maximizes protein production. R-301 A/B is prepared for inoculation by pumping in 
16,500 L of Growth A media from V-103 through P-104. The cells are then inoculated in the 
reactor and allowed to incubate for 9 days. During this time, 366 L of BalanCD CHO Feed 4 
media are pumped from V-105 A/B to the reactor by P-106 each day. The total amount of Feed 
4 media added to the production bioreactor is 20% of the volume of the Growth A media added 
to the same reactor [17] The purpose for adding Feed 4 media to the reactor is to maintain the 
glucose level within the reactor above 2 g/L, as well as to make sure that amount of nutrients is 
not a limiting factor to culture growth. R-301 has the same compressed air, cooling jack, 
impeller, and vent systems as described above for R-207 and R-208. 15 m3/min of air and 1823 
kg/hr of cooling water are provided to the reactor. In order to decrease the cycle time (time 
between batches) of the process, two identical Production Bioreactors and Feed Media Prep 
Vessels were designed. Each successive batch will switch between using R-301A and R-301B so 
that cells are always in one of the reactors. 
 
Primary Recovery: Harvest 
The solution leaving the production bioreactor, R-301 A/B, contains a variety of substances 
including cells, proteins (especially mAb), water, media, nutrients, and soluble gases. Once the 
mAb has been produced, the solution needs to be purified by removing any unnecessary 
components and concentrating the mAbs in solution. The production slurry, a total of 23,325 
kilograms per batch, leaves the production bioreactor and is sent to Production Bioreactor 




surge tank, the reactor product drains out, in four equivalently-apportioned cycles, to 
centrifuge Cf-304.  Here, the suspension is separated into layers based upon the density of the 
components via centrifugal force, and the cells are separated into their various components 
(lipids, proteins, water, etc.). Gravity serves to take 823 kg per batch of solid waste to Waste 
Holding Tank, Tk-701. The Centrifugal Pump, P-305, sends the other 22,463 kg per batch of 
liquid cell culture broth through Dead-End Filter 1, F-306, where any remaining cell solids or 
solid impurities are removed. The pores in the filter membrane are 0.2 µm in diameter, too 
small for cells to pass through, but large enough that smaller components, as well as those that 
are soluble, can pass through. From F-306, a cell-less solution is collected in Tk-307, where it 
awaits further purification. Any waste remaining in F-306 also collects in Tk-701.  
 
Buffer Prep 
In order to purify the mAb product, the solution must pass through multiple chromatography 
columns. These columns selectively bind to certain molecules in the solution while allowing 
others to pass through freely. Each column uses multiple types of buffers to process the 
solution: equilibration, wash, elution, and regeneration buffers. These buffers contain unique 
formulations of various chemicals, for which these specific formulations can be found in Table 
17 in the Column Chromatography section of Equipment List and Unit Descriptions. For the first 
chromatography column, Protein A Chromatography, a total of four different buffers are 
prepared. The equilibration, wash, elution, and regeneration buffers are prepared in impeller-
mixed vessels V-401, V-402, V-403, and V-404 respectively. A total of 2507, 4146, 8219, and 
5097 kg/batch are prepared in the aforementioned vessels, respectively, before being pumped 
through Cl-406 via P-405. For the Cation-Exchange Chromatography Column, V-501, V-502, V-
503, V-504, and V-505 are utilized for the preparation of buffers. These vessels are utilized for 
the equilibration, first wash, elution, regeneration, and final wash buffers, preparing 1405, 
2345, 4806, 2387, and 1406 kg/batch, respectively, before sending them through the Cl-507 via 
P-506. Lastly, V-601, V-602, V-603, and V-604 are utilized in the preparation of the Hydrophobic 
Interaction Column buffers for equilibration, wash, elution, and regeneration, respectively. 
2002, 3337, 6453, and 3161 kg/batch of these respective buffers are prepared in the vessels, 
followed by P-605 sending them through Cl-606. 
 
Purification: Protein A 
 With the liquid cell culture broth in Tk-307, the equilibration buffer from V-401 is sent through 
the Protein A Chromatography Column, Cl-406, at 300 cm/hr in order to prepare the 
environment of the column to maximize mAb affinity. Then, the liquid cell culture broth, in two 
equivalent cycles, is loaded through Cl-406 at a linear velocity of 500 cm/hr in order to remove 
impurities. The Protein A column operates in a bind-elute mode, in which the mAb proteins 
bind to the protein A present on the column resin. Their affinity for the resin allows them to 
remain in the column after the liquid has been loaded through it, while other impurities flow 
through the column and into the waste stream. Five bed volumes of wash buffer from V-402 is 
then sent through the column at 300 cm/hr, cleaning any remaining impurities from the 
column. Now that impurities have been washed from the column, ten bed volumes of elution 




flowing from Cl-406, through F-407 in order to filter out any potential aggregates or solids, and 
into the Viral Activation Vessel, V-408. Lastly, Cl-406 is regenerated by five bed volumes of 
buffer solution from V-404 at 300cm/hr. 
 
Viral Inactivation 
Two orthogonal viral inactivation steps are required for biopharmaceutical processes per FDA 
requirements [7]. These processes are designed to change the environment of any viruses that 
it denatures their protein structure such that they are rendered inviable. Any microbes, 
especially pathogenic, are a serious threat not only to cell cultures but to the public who 
consume pharmaceutical products. As such, these steps of the process are some of the most 
important. 
 
After the process materials have gone through the protein A chromatography column, Cl-406, 
the 1687 kg of purified solution is collected in the Viral Inactivation Vessel, V-408. The elution 
buffer from the protein A column has a low pH and therefore can be used for viral inactivation. 
The purified solution is held in the surge tank with the elution buffer for 90 minutes to 
effectively inactivate any viruses [7]. Next, the stream is diluted with 500 L WFI and sent to 
Diafiltration Flush Tank 1, Tk-410. From this tank, the solution is pumped through Diafilter 1, F-
412, and back to V-108 by Diafiltration Pump 1, P-411. While passing through the diafilter, 
soluble particles and liquids are separated from the product stream and sent to waste. After the 
solution has been washed in the diafiltration system and returned to the same viral inactivation 
vessel, V-508, 10.3 L of Polysorbate 80 solution is added to the 339 L of concentrated product 
solution and held for 90 minutes. This solution acts as a surfactant to break down lipids in the 
viruses, thus rendering them inactive. After the solution has been properly inactivated, it is 
filtered through Dead-End Filter 3, F-413, and sent to the Viral Inactivation Surge Tank, Tk-414, 
to await further purification. The 2025 kg of waste from F-412 are collected in Tk-701.  
 
Purification: Polishing 
 While Protein A Chromatography is able to remove the vast majority of, and in some cases up 
to 99.5% of non-mAb components in the solution, we must still send the broth through 
polishing steps in order to ensure a pure mAb product before final storage and formulation. 
The first step in this polishing process is Cation-Exchange Chromatography, through Cl-507. 
From Tk-414, 347 kilograms of remaining cell broth is pumped via P-506 through Cl-507 at 500 
cm/hr. As the equilibration buffer has already been sent from V-501, the pH of the column is 
below the isoelectric point of the mAb proteins. This environment makes the protein positively 
charged, causing it to bind to the negatively charged CEX resin, while other uncharged or 
positively charged impurities flow through the column and to the waste. After wash and elution 
from Cl-507, the solution flows into the Ammonium Sulfate Vessel, V-508. 102 kg of ammonium 
sulfate is added to V-508 and mixed for 30 minutes in order to precipitate mAb proteins out of 
the solution. The solution is then diluted with WFI and sent to Diafiltration Flush Tank 2, Tk-509, 
via P-605. It is passed through the diafilter, separating waste, after which the process stream is 
pumped to Cl-606. Cl-606 is the Hydrophobic Interaction Column, the last step in the polishing 




602, V-603, and V-604, the HIC equilibration, wash, elution, and regeneration buffers, 
respectively, are pumped via P-605 through each step of the HIC Chromatography. The bound 
and then eluted mAb in 1322 kg of solution are sent to HIC Surge Tank, Tk-607. The solution is 
once again diluted with WFI and sent through Diafilter 3, F-611, via P-610 before being sent 
through the last dead end filter F-612. 
 
Storage of Product 
After the final polishing steps, the product needs to be packaged and stored for sale. 260 kg of 
product is drawn out of the final filter and fed into twenty-two 12 L storage bags. Due to the 
biological nature of the components, the mAb product needs to be frozen in order to preserve 
the protein structure. To do so, eight storage bags at a time are placed in the Freeze-Thaw 
Cryovessel, V-613. V-613 provides controlled cooling from 25 to -50°C over the course of 4.5 
hours [18]. This uniformly entraps solute molecules and prevents prolonged freeze-
concentration stress. After each freeze cycle, the now-frozen solution in the storage bags are 
removed from V-613 and placed into the Storage Freezer, Fz-614, at -50 C. The mAbs are viable 
in their frozen state for at least one year. 
 
Waste Treatment 
Throughout the process, all 129000 kg of waste produced is collected in the Waste Holding 
Tank, Tk-701. The waste streams come from CIP and SIP streams, filter waste, centrifuge waste, 
and column waste. These materials must be treated so that they can be disposed of through 
the municipal sewage system. The waste from Tk-701 is continuously pumped by Waste 
Holding Pump, P-102, to the Neutralization Vessel, V-703 at a rate of 768 kg/hr. While the 
stream is traveling to the neutralization vessel, 80 kg/hr of saturated steam is continuously 
injected into the line, raising the temperature of the waste from 25 to 83°C. The heated waste 
collects in the neutralization tank. Here 36 kg of 37% (w/w) aqueous hydrochloric acid is added 
to the waste to bring the pH of the solution within the acceptable range. After the contents of 
the vessel have been mixed by an impeller for 30 minutes, the vessel is emptied into the 
municipal sewage system and more waste begins collecting in the neutralization tank. 
 
Water for Injection 
Producing pharmaceutical components requires high standards of purity and sterilization. As 
such, it was a necessity to use WFI throughout the process. For water to be classified as WFI, it 
must meet certain standards of purity and composition [11]. Although this water can be 
purchased in bulk, it is more cost-effective to design a system to make water for injection from 
potable water. 
 
The WFI production system begins with the Potable Water Tank, Tk-801. This tank stores 1450 
kg/hr of potable water from the city and 120 kg/hr of water from different points in the 
process. This water solution is pumped from Tk-801 through Dead-End Filter 5, F-803, to the 
Carbon Adsorption Column, Cl-804, by Potable Water Pump, P-802. F-803 removes any solid 
impurities, including bacteria, from the stream. In the carbon adsorption column, organic 




order to maximize the productivity of the WFI process, two carbon columns operate on a 
cycle—while one is in operation, the other is being regenerated by washing with 75 L each of 
water, 0.5 M NaOH, and 0.5 M HCl. After leaving the carbon adsorption column, the water 
enters the Cation Exchange Column, Cl-805 and then the Anion Exchange Colulmn, Cl-806. In 
these columns, the stream is purified of cations and anions respectively as they bind to the 
adsorbents. These columns also undergo a wash once per batch of the process. After 
undergoing ion exchange, the stream is purified of any fine particulate matter through the 
Ultrafilter, F-807. The pore size on these filters are 100 D, leading to a high filtering ability [19]. 
After F-807, the stream finally enters F-808, the Reverse Osmosis unit. This final unit removes 
any leftover contaminants in the water. Lastly, 1531 kg/hr water enters a Purified Water Tank, 
Tk-809. Although this process is designed to run continuously, the process will need to be shut 
down once per batch to wash the activated carbon, cation exchange, and anion exchange 
columns with buffers that will remove any adsorbed materials and help maintain optimal 
purification of the water. The waste from the adsorption columns and dead-end filter are sent 
to process waste, while the waste streams from the ultrafiltration and RO units are recycled to 
the inlet of the potable water tank and recycled through the process. 
 
After being processed through this filtering system, the once potable water can be classified as 
purified water. In order to complete the production of WFI, the water is pumped from the 
Purified Water Tank, Tk-809, through a series of heat exchangers to the Steam Boiler, HE-813, 
by Purified Water Pump, P-810. The first heat exchanger the water is pumped through is 
Purified Water Pre-Heater, HE-811. In this heat exchanger, the 1100 kg/hr of impure hot water 
leaving the bottom of the steam boiler heats the purified water from 25 to 29°C. In the second 
heat exchanger, the WFI Condenser, HE-812, the 1100 kg/hr of vaporized water for injection is 
condensed at a pressure of 3.24 bara as the purified water is further preheated to 105.7°C. 
Next the preheated, purified water enters the steam boiler where it is heated by an electric coil 
providing 166.5 kW of heating and a steam coil carrying the compressed steam from the boiler 
providing 77.89 kW of heating. As the water is boiled, it enters a compressor which superheats 
the steam by increasing the pressure from 1.24 to 3.45 bara and the temperature from 105.7 to 
245.8°C. This superheated steam is then circulated through the steam coil where it is cooled 
from 245.8 to 136.1°C such that the steam is now saturated. From here 200 kg/hr of steam is 
drawn off for steam injection into the waste treatment line and for steam in place of the 
process. The rest of the steam (1100 kg/hr) is condensed in HE-812 and pumped to the WFI 
Storage  
 
Tank, Tk-818, via WFI Storage Pump, P-817. Here the WFI collects until it is needed in the 
process. The WFI Process Supply Pumps 1 and 2, P-819 and P-820, pump water from Tk-818 
throughout the entire process at a maximum of 30,000 L/hr. The 68.4 L/hr of water that exits 
the bottom of the boiler, HE-813, is pumped through the purified water preheater, HE-811, and 
recycled back to the potable water tank at the beginning of the WFI process.  
 
Steam in Place and Clean in Place 
The final part of the process is the SIP and CIP system. This system is one of the most important 




maintaining the proper environment for mAb production. The SIP for the SIP system is 
produced during the WFI process and is simply stored in the SIP lines until it is needed. The CIP 
system is comprised of three vessels, V-901, V-902, and V-903, and a pump, P-904. Each vessel 
is used to prepare and store a different cleaning solution. Caustic Vessel 1, V-901, is used to 
prepare 0.5 M NaOH for cleaning the chromatography columns. In order to prepare this 
solution, 20g of solid NaOH is added to the vessel for every one liter of WFI. Caustic Vessel 2, V-
902, is used to prepare 0.1 M NaOH for cleaning the rest of the vessels. For this solution, 4g of 
solid NaOH is added to the vessel for every L of WFI. Acid Vessel 1, V-903, is used to prepare 0.1 
M HCl. This solution is prepared by mixing 2.47 L of 37% (w/w) HCl per L of WFI. The total 
amounts produced of each solution per batch are 6,063 L, 17,035 L, and 27,170 L for V-901, V-
902, and V-903 respectively. CIP Pump, P-904, supplies the CIP solutions for the entire process 
and can supply up to 1200 L/hr. After each unit has completed its operations, different 
solutions are cycled through to remove any leftover waste or impurities. For all units except 
chromatography columns, respective cycles through the unit are WFI, 0.1 M NaOH, WFI, 0.1 M 
HCl, and WFI. Chromatography columns only have two CIP cycles- one 0.5 M NaOH cycle and a 
WFI cycle. The flow amounts for each unit are based upon equipment heuristics, summarized in 
Table 10 below. 
 
Table 10: Heuristics  
 
 
Process Scale Up 
One of the most important parts of designing this process is accounting for the potential to 
scale up the process in the future. There are a few ways this process could be scaled up to 
increase production. The first is mentioned in the design parameters for the project—increasing 
the mAb titer from 1-2 g/L to 5-10 g/L. This increase in the process titer could be accomplished 
by harvesting the cells from each step in the seed train at a larger cell density. By allowing the 
culture to grow longer in each step of the seed train, the amount of mAb produced in each step 
increases while the volume stays constant, effectively increasing the titer. Additionally, an 
increased amount of Feed 4 media can be fed to the production bioreactor through the 
process. This would give the culture more nutrients to use for growth, allowing the titer to 
continue to increase.  
 
Another way to scale up the process is to build multiples of the entire process so that each 
process can be run individually. This will greatly increase the capital and operating costs, but it 
will also greatly increase the revenue. Although having multiples of the entire process running 
simultaneously works, the most effective way to scale up the process is by continuing to add 
staggered units to remove bottlenecks in the process. This method was used in this design by 




bottlenecks in the process are removed, more batches can be processed per year, meaning 
more product is produced and more revenue is generated. This method is more effective than 
having multiples of the entire process because it prioritizes increasing the capital cost on adding 
units that will affect your cycle time rather than on those that won’t.  
UTILITY REQUIREMENTS 
 
One of the most important manufacturing costs to account for when analyzing the economics 
of a project is the utility cost. Table 11, 12, and 13 summarize the electric, water, and sewer 
utility requirements and costs for the entirety of the project life. 
 









Table 12: Water Utilities   




EQUIPMENT LIST AND UNIT DESCRIPTIONS 
 
Seed and Production Bioreactors 
The CHO cells for this design are provided in 1 mL 
vials containing 1 x 106 cells per vial. Each seed 
train may only use 1 vial for each batch of 
bioreactor product. Cell cultures go through four 
different phases: lag phase, log phase, stationary 
phase, and death phase. A generalization of the 
phases are shown in Figure 8.  
 
The goal in designing the seed train is to keep cells 
in the log phase for as long as possible, because in 
the log phase the culture grows exponentially. 
Exponential growth of cells is modeled by the following function: 
A = Aoert       (1) 
where A is the current number of cells, Ao is the initial number of cells, r is the growth rate 
constant (1 / hours), and t is time (hours). In the problem statement, the doubling time for CHO 
cells was stated to be 36 hours, meaning when A=2*Ao when t=36h. With a doubling time, the 
above equation can be solved for r; for these CHO cells r=0.019254 (hr-1). With this rate 
constant, the amount of time needed to obtain a certain number of cells from an initial amount 
of cells can be calculated. The main factor that determines whether a culture will remain in the 
log phase is the concentration of nutrients in the media. Powdered BalanCD® CHO Growth A 
Medium, a serum-free and chemically defined media, is used in the seed train. The media has a 
reported maximum cell viability of 9.0 × 106 cells/mL [8]. Cells are often inoculated into BalanCD 
media at a density of 2.0 × 105 cells/mL [8]. These two facts set the upper and lower limits for 
each seed train step. 
 
The seed train was designed to inoculate each vessel at 2.0 × 105 cells/mL and harvest at 
4.0 × 106 cells/mL. This lower harvest density than the reported maximum was selected in order 
to guarantee that the cells were still in the log phase throughout the entire culture. Using these 
densities and the initial amount of cells in the first step, as well as the exponential growth 
equation, Table 14 was created.  
 
Table 14: Seed Train Steps 
 
Seed Train Step 1 2 3 4 5 6 Prod Bio
Initial Cells 1.00E+06 5.00E+06 1.00E+08 2.00E+09 3.50E+10 7.00E+11 1.40E+13
Final Cells 5.00E+06 1.00E+08 2.00E+09 3.50E+10 7.00E+11 1.40E+13 2.10E+14
Time (hrs) 83.6 155.6 155.6 148.7 155.6 155.6 140.6
Time (days) 3.48 6.48 6.48 6.19 6.48 6.48 5.86
Volume (mL) 5.00 25.00 500 1.00E+04 1.75E+05 3.50E+06 1.40E+07
Volume Added (L) 0.005 0.02 0.475 9.5 165 3325 10500
Inoc Density (cell/mL) 2.00E+05 2.00E+05 2.00E+05 2.00E+05 2.00E+05 2.00E+05 1.00E+06
Harvest Density (cell/mL) 1.00E+06 4.00E+06 4.00E+06 3.50E+06 4.00E+06 4.00E+06 1.50E+07
mAb Produced (kg) 4.35E-07 1.62E-05 3.24E-04 5.42E-03 0.113 2.27 30.77
mAb Sum (kg) 4.35E-07 1.66E-05 3.41E-04 5.76E-03 0.119 2.39 33.15





In this table, the amount of media that was needed for a particular step was calculated by 
diluting the total number of cells at the beginning of that step to the desired inoculation 
density. Next, the final number of cells in each step was calculated by multiplying the desired 
harvest density by the total volume of the culture. Finally, the exponential growth equation was 
used to solve for the total amount of time the cells would need to grow exponentially in order 
to reach the final culture size. Table 14 was used to determine the size of the vessel in each 
seed train step, how long the cells needed to remain in that step, as well as how much media 
needed to be added to the previous broth to reach the desired volume. The last two rows in the 
table calculate the amount of mAb produced during each step and a running total of all the 
mAb produced so far. These values were calculated by multiplying the number of cells at any 
point in time by the mAb production rate of 25 pg(mAb)/cell.day.  
 
The size of each seed train vessel was determined based on the maximum total volume that it 
would contain. For the smaller volumes, a culture vessel was chosen that was one nominal size 
greater than the volume required per batch. The vessels that were chosen are a 10 mL t-flask, a 
35 mL t-flask, a 1 L roller bottle, and a 15 L cell bag. All of these vessels are sterile and 
disposable, which leads to lower operating costs and higher raw material costs. The bulk cost 
for each of these items as well as the roller bottle roller and cell bag rocker were found from 
online retailers [20,21]. 
 
The final two seed culture bioreactors and the production bioreactor were sized using the total 
volume each would contain during each batch. For the seed culture bioreactors, this volume is 
equal to the volume in the chart above. For the production bioreactor, this volume is equal to 
the volume in the chart plus 3,300 L for the Feed 4 fed-batch media. The maximum working 
capacity for each vessel is 90%, so the maximum volume was divided by 90% and then rounded 
up to the nearest whole number (in m3). The sizes for the bioreactors are as follows: R-207 is 
.25 m3, R-208 is 5 m3, and R-301 is 30 m3. 316L stainless steel was selected as the material of 
construction for the reactor due to its high resistance to corrosion and its sterile nature. For 
more details about the bioreactor sizing and costing, see the Vessels and Tanks section below. 
 
Vessels and Tanks 
All vessels and tanks in the process were sized based upon the maximum fluid volume that 
might be held in the vessel during a batch. This maximum volume is divided by a 90% working 
capacity factor and then rounded up to the next nominal size to determine the actual size of 
the vessel. The maximum fluid volumes and actual size of the tanks and vessels in the process 
are shown in Table 15 below. All vessels and tanks are made out of 316L stainless steel because 











Table 15: Fluid Volume Compared to Tank and Vessel Volume 
 
Compressors 
In our process, we have both an air and a steam compressor. The air compressor allows us to 
provide sterile, compressed air to the bioreactors at 25 psia.  The steam compressor drives the 
flow of the steam for both steam-in-place and waste steam injection at 50 psia. The power of 
each of the compressors was calculated based on the ideal work, gas horsepower, mechanical 
losses, brake horsepower, and adiabatic efficiency from the GPSA Handbook [22]. This method 
assumes: 
 
• Mechanical losses are equal to (GHP)0.4 
• Compression follows a polytropic path 
 
The team determined that both of the compressors would best operate as centrifugal single-
stage compressors. This was determined using inlet flow, discharge pressure, and Figure 9, 






Figure 9: Graphical display of suitable compressor operating ranges for compressor type 
selection [22] 
 
To size the compressor drives, the overall BHP were rounded up to the next available standard 
drive size, as outlined by [23]. 
  
Centrifuge 
After the cells and broth leave the production bioreactor, they are sent to the first harvesting 
step, centrifugation in Cf-304. The centrifuge is scheduled to perform four cycles per batch, 
processing 5831 kilograms per cycle in order to reduce the overall size and capital cost of the 
equipment. In order to design the centrifuge itself, the overall settling area ∑ was set at a 
maximum value of 130,000 m2, based upon the suggested upper limit for an industrial-size 
centrifuge [7]. From this maximum ∑ value, the overall throughput was determined to be 1470 
L/hr based off of calculations performed by SuperPro Designer. 
 
Pumps 
In bioprocessing industries, pumps are required to move 
fluids through tubing into processing equipment. These 
fluids can be buffer, media, WFI, or the biological broth 
itself. They must be selected and designed to minimize 
shearing and agitation of the biological fluids in order to 
protect against degradation that could diminish product  
quality. Diaphragm metering pumps have been selected 
for all applications in this design for their highly accurate 
volume control necessary in processes and for dosing [24].  A diaphragm pump operates by 
lifting and pressing a flexible seal on top of the chamber to suck in fluid during the lift and 
closing the outlet by creating a negative pressure gradient and entrapping that liquid in the 
pump fluid chamber. The movement is shown in Figure 10. Then, the diaphragm is pushed 




down to create a positive pressure gradient, resulting in opening of the exit, closing of the inlet, 
and positive displacement  of the fluid without creating a net pressure effect on the process 
stream. These motions are powered by an electric motor. Also, the diaphragm separates the 
pump drive from the product-wetted side. This separation means that mechanical seals are not 
needed, which ensures product sterilization, simplifies maintenance, and allows the pump to 
run dry [24]. Being able to run dry for a limited amount of time is a significant advantage that 
will allow the pumps to pull from different sources depending on valve configuration 
considered in the detail design, thus reducing the number of pumps required in the process. 
Applications for diaphragm positive displacement pumps include: chromatography, buffer inline 
dilution, homogenization, injection of fluids (e.g., liposomes) into extruders, coating operations, 
filling, caustic dilution, and aseptic transfer of proteins, cells, and other materials [24], which 
meet all demands of this design. It is also common practice to use pumps in diafiltration units. 
Costing information for the pumps and motors used in running these pumps is listed in Table 18 
in the Fixed Capital Investment Summary.  
 
Placement and quantity of pumps is considered for the main components of this preliminary 
design. Exact specifications and additional pumps of non-key process components can be 
completed in the detailed design stage if this project is pursued further. Areas without pumps 
in between process equipment can either be assumed to have pressure from previous pumps in 
combination with valve configurations sufficient enough to move the material to their desired 
locations, or to utilize gravity by placement of equipment below the previous process to move 
process flow, such as the Production Bioreactor Surge Tank (Tk-203) being designed to drain to 
the centrifuge. An example of a pump being used for multiple streams would be the Protein A 
Column Feed Tank (P-405 A/B). If valves and control systems are configured correctly during 
detailed design, this pump will be able to buffer the column by first emptying the contents of V-
401, then run dry while the valves switch to allow the contents of V-402 to flow into the 
column, and continue that process until all buffers have been loaded. Next, the pump and 
valves could operate by transferring in the contents of the centrifuge Surge Tank (Tk-307). This 
capability coupled with the process design greatly reduces the number of pumps that would be 
placed in the facility. Pumps are not required in the preliminary stages of the seed train 
because the cell cultures will be transported by trained personnel due to the minimal size and 
delicate nature of the early seed train stages.  
 
Table 16: Pump Sizes [25] 
 
Sizing these pumps depends solely upon the flow required in a process stream. Due to the 
nature of the diaphragm pump, a net pressure difference is not put on the streams due to the 
Pump Flow Range (Lph) Max Pressure (bar) Motor Power (kW)
QF150 1-150 6 0.05
QF1200 6-1,200 6 0.37
QF4400 60-4,000 6 2.20
QF10K 500-10,000 6 3.00




lift and press motion of the diaphragm that pulls in a volume of liquid to the pump and pushes 
it out. So, pressure of the stream must only be less than the maximum allowable working 
pressure of the pump (6 bar for each pump). Because there is no pressure greater than 6 bar in 
the process design, pressure is not a factor in pump selection. Table 16 is referred to in order to 
select the correct size for each pump in the design. All that needs to be known to  
select the size is the maximum and minimum flowrates. There are twenty four QF1200 pumps 
in the process: P-102 A/B, P-104 A/B, P-106 A/B, P-302 A/B, P-305 A/B, P-409 A/B, P-411 A/B, P-
510 A/B, P-608 A/B, P-610 A/B, P-816 A/B, and P-904 A/B. There are fourteen QF10k pumps in 
the process: P-405 A/B, P-506 A/B, P-702 A/B, P-802 A/B, P-810 A/B, P-817 A/B, and P-820 A/B. 
There are four QF20k pumps in the process: P-605 A/B and P-819 A/B (Figure 11). A relatively 
low flowrate of 600 L/hr was selected for all streams containing CHO cells in order to protect 
the cells; therefore the majority of pumps were QF1200s. The flowrates for pumps serving 
chromatography columns were set by the column loading rate. The rest of the flowrates were 
determined by the desired production need i.e. the amount of water being pumped through 
the WFI system is determined by the total WFI production demand of 1300 kg/hr. The largest 
flowrate in the process is the WFI stream leaving the WFI Storage Tank (Tk-818) due to 
instantaneous WFI demand. This need can reach 29,000 liters per hour, and was outside of the 
range of the largest pump size. This issue was resolved by placing a 10,000 liter per hour 
(QF10k) pump in parallel with the 20,000 liter per hour (QF20K) pump to meet maximum 
instantaneous demand for WFI. Pump P-819 A/B, the 20,000 liter per hour pump, will always be 
running to provide WFI to the process and the other pump will only turn on if the demand 
reaches above 20,000 liters per hour.  
 
Figure 11: Varying pump sizes [25] 
 
Dead-End Filters 
Dead-end filters are used throughout the process to remove unwanted solids, particularly 
biomass (CHO cells) and suspended impurities, from the product stream. The pore size for 
pharmaceutical dead-end filters is 0.2 μm, significantly smaller than the average mammalian 
cell size. Advantages of using dead-end filters include a very low capital cost and high recovery 
of product solution from bioreactor slurry. The required membrane surface area for each filter 
was calculated based upon the flow rate of the stream through the filter, which was usually set 
by the flow rate to or from some other point in the process. SuperPro Designer was used to 
model each dead-end filter, and the required surface area for each filter was determined using 
that model. The following surface areas were calculated for the various dead-end filters: 230 m2 
for F-306, 80 m2 for F-407, 80 m2 for F-413, 70 m2 for F-612, and 120 m2 for F-803. For all of the 
dead-end filtration units, 316L stainless steel is the material of construction for the filter 





Diafilters and Ultrafilters 
Diafilters are used in this process to remove small particulates, soluble molecules, and non-
water liquids from the product stream. These systems are capable of removing both small solid 
and liquid impurities through the use of multiple water flush cycles that dilute and concentrate 
the stream until only the desired components are left. For each diafiltration system, the inlet 
stream was diluted with 40% of the stream volume in WFI. Additionally, 500 L of water was 
flushed through the unit to aid in filtration. The product stream was concentrated 5 times 
through the filtration and the majority of chemicals and contaminants introduced into the 
stream at the previous chromatography column were removed. The required filter surface area 
for each diafiltration unit was calculated using the product stream and WFI diluant volumes 
inputted into a SuperPro Designer model. The required membrane areas are 26 m2 for F-412, 
16 m2 for F-511, and 20 m2 for F-611. 
 
Ultrafilters are used in the WFI system to filter out very small suspended particulates from the 
water supply. Ultrafiltration membranes, along with the diafiltration membranes, have pore 
sizes that are 100 D, much smaller and finer than the pore sizes for dead-end filtration [19]. The 
required surface area for the ultrafiltration unit was determined using a SuperPro Designer 
model based upon the total water flow through the WFI system. The required membrane area 
for F-807 is 40 m2. The same filters were selected for both the diafilters and ultrafilters [19]. For 
all of the filtration units, 316L stainless steel is the material of construction for the filter 
housing, and pharmaceutical friendly membranes are selected. 
 
Chromatography Columns 
This preliminary design utilizes three different chromatography columns to purify the mAb 
product stream. All three of the columns-Protein A, Ion Exchange, and Hydrophobic Interaction-
are filled with an adsorptive resin and constructed of stainless steel to maximize sterilization 
and minimize impurities due to rust and corrosion. Figure 12 is an example of this type of 
column: 
 





In each of these columns, the goal is to bind the target protein, mAb, to the column resin and 
let impurities flow through. Affinity for Protein A, charge, and hydrophobicity are the 
characteristics, respectively, that each column is utilizing to target the mAbs. 
 
Protein A 
In order to design the Protein A Chromatography Column, some assumptions were required. 
Utilizing heuristics and common values from an article by Marichal-Gallardo and Alvarez, we 
assumed that the dynamic binding capacity of the resin is 55 g/L, the linear velocity of each 
buffer loading step is 300 cm/hr, and the bed height is 25 cm [7]. The final parameter needed to 
determine the overall bed volume of the chromatography column was the productivity of the 
column. As seen in the equations below, maximizing the productivity of the column increases 
the mass of product processed for a given column volume and time.  
 
Productivity (P) = (Mass of product/column volume)/time       (2) 
                                                             
      (3) 
 
In the simplified second equation, L refers to the column bed height, CO to the column loading 
concentration, uL to the velocity of the load step, N to number of column volumes in non-load 
steps, uN to velocity of non-loading steps, and Qd to binding capacity. While most of the 
parameters were estimated, the velocity of the load step was increased up to the maximum 
load velocity of 500 cm/hr in order to maximize the productivity at the assumed column 
conditions. From this, we determined the optimal productivity to be 20.95 g/L*hr. From the 
estimated parameters and now-determined load velocity, a required bed volume of 413 liters 
was specified by SuperPro Designer. In order to determine what Protein A resin to buy for the 
process, several selection guides were considered. One resin in particular, mAbSelectSure, fits 
the capacity needs of our process, has a high binding capacity, and has a low affinity for host 
cell proteins, particles that tend to compete with mAb for resin binding positions [26]. 
 
IEX and HIC 
Both the Ion Exchange and Hydrophobic Interaction Chromatography columns are integral 
components of the downstream polishing process. A similar approach to the previously stated 
PA Column design process was taken to determine the size and parameters of each of the two 
columns in the polishing process. The main change with regard to our assumptions about the 
IEX column was the dynamic binding capacity of the resin. The average dynamic binding 
capacity of an IEX resin is much higher than that of a Protein A resin, thus a DBC of 85 g/L was 
chosen [7]. The productivity of this column was determined to be 55.02 g/L*hr with the same 
maximum linear velocity of 500 cm/hr. The concentration of the IEX loading solution was much 
lower than the loading concentration of the Protein A column inlet, thus only a bed volume of 
233 L was determined for its design. Using a selection guide similar to that which was used for 
Protein A resin, it was determined that Unosphere S Support Cation Exchange resin was the 




as high DBC [27]. For Hydrophobic Interaction Chromatography, similar design guidelines to 
Protein A Columns were provided, thus a DBC of 55 g/L was assumed, as well as the same non-
loading linear velocity of 300 cm/hr. Lastly, a productivity of 43.4 g/L*hr was calculated based 
on a 500 cm/hr loading flow rate. It was determined that the required bed volume for the HIC 
column is 629.5 L. The HIC resin, Methyl HIC Support was chosen as the resin due to its 
minimization of protein denaturing and affinity toward bimolecular hydrophobic regions [28]. 
 
Buffers 
For each chromatography column there are various buffers with their own unique formulation. 
Equilibration buffers prepare a column for loading a sample by washing out any impurities and 
setting the proper pH. Wash buffers remove any molecules that haven’t bonded to the column 
resin, leaving behind only the resin and the bonded molecules. Elution buffers change the 
environment inside the column in such a way that the molecules that were bonded to the resin 
are released. Regeneration buffers clean the column by removing any leftovers of the previous 
buffers and prepare the column to wait for the next load. The different buffer compositions for 
each column can be found below in Table 17. 




For Protein A Chromatography, an equilibration, wash, elution, and regeneration buffer are 
prepared and sent through the column. The compositions of each of these buffer solutions 
were chosen based upon suggested compositions from both Bio-Rad and ThermoFisher [29]. 
One important consideration was that the elution buffer would provide a pH of 3 or lower, 
allowing for effective viral inactivation in V-408.  
 
IEX Chromatography, or in this case Cation Exchange Chromatography requires five buffer 
solutions: equilibration, first wash, elution, regeneration, and second wash. The 
compositions of these buffers were determined both by the compatible buffer formulations 
from Marichal-Gallardo and Alvarez as well as considerations to guidelines from Bio-Rad and 
Pall, Inc. [30]. The most important aspect of this CEX buffer composition was to maintain a pH 
of around 6 pH, 1-1.5 pH below the isoelectric point of the antibody [31]. This ensures that the 
antibody is positively charged, and thus will bind to the CEX resin rather than flow through. 
 
HIC Chromatography requires four different buffer solutions, also for an equilibration, wash, 
elution, and regeneration step. However, rather than each of the buffer solutions being 
different in component, the first three only differ in composition. The equilibration buffer has a 
strong concentration of sodium chloride in water, salting out the mAb proteins to allow for 
easier binding to the hydrophobic areas of the resin [32]. As the buffer steps continue to wash 
and elute, the concentration decreases, creating a concentration gradient and allowing the 
mAbs to release from the resin. The final step consists of sodium hydroxide and water, helping 
to release tightly-bound proteins [32]. 
 
Adsorption Columns 
The WFI process utilizes three different adsorption columns to purify potable water. The 
activated carbon, cation exchange, and anion exchange columns were all sized in a similar 
manner, although they use different resins and serve to purify the water in different ways. The 
vessels for all three columns were sized as a regular tank, in a similar manner to the way 
described in the Vessels and Tanks section above. For the activated carbon column, the bed 
volume was calculated to be 276 L using a SuperPro Designer model with breakthrough time of 
7 days (one complete process batch) and a water inlet flow of 2042 L/hr. Assuming a 
bed/column volume ratio of 0.5, the required vessel volume for Cl-804 A/B is 552 L and the 
actual vessel volume is set at 0.625 m3. The same process was completed for Cl-805 and CL-806 
leading to required volumes of 212 L and 175 L and vessel sizes of 0.25 m3 and 0.20 m3 
respectively. All of the columns are to be made out of 316L stainless steel because of its anti-
corrosive and sterile properties. 
 
The volume of adsorbent for each column was calculated as half the total volume of the 
column. Granular activated carbon comes in a variety of sizes; 12 x 40 was chosen for the 
column because it is one of the most popular sized for aqueous phase adsorption [ ]. For the 
cation exchange column, the same resin was chosen as the resin in the mAb ion exchange 
column, UNOsphere S Media. AG 1-X2 was selected as the resin for the anion exchange column 
because of high resistance to oxidizing agents and ability to adsorb for long periods of time 




solutions from the CIP system, making the cleaning process simpler and easier. Chemical 
reactivation of the activated carbon adsorbent with 0.1 M NaOH and 0.1 M HCl will occur after 
each batch to maintain optimal adsorption [34]. The anion and cation exchange columns are 
washed with 0.1 M NaOH and 0.1 M HCl respectively to clean the resin and prepare for the next 
batch. All of the modeling for these wash steps were performed in SuperPro Designer assuming 
3 bed volumes of wash per solution per batch.  
 
Reverse Osmosis 
Reverse osmosis is one of the most prevalent methods for water purification, even being used 
to desalinate sea water. In this process, the reverse osmosis system serves as final purification 
“catch-all,” removing any contaminants that were left over after the water was processed by 
the previous systems. Due to the complication of reverse osmosis membranes, a prepackaged 
RO skid sold by US Water Systems was selected to be used in the process [35]. The skid size was 
selected based upon the 11,000 gpd throughput required by the WFI process. Although they 
don’t have a standard skid that can product that level of throughput, a US Water Systems 
employee confirmed that the price of a skid that size could be scaled up from the price of the 
largest skid using the six-tenths rule. The skid comes with standard filters, and replacements 
were also available through US Water Systems [36]. 
 
Air Cartridge Filter 
In order to sterilize the air being brought into the bioreactor aeration system, an Air Cartridge 
Filter, F-210, is placed in the process stream before the Air Compressor, C-211. The total 
continuous air supply amount required to aerate the bioreactors was sent through a simulated 
dead-end filter to calculate the required membrane surface area of the filter. It was determined 
based upon this SuperPro Designer simulation that the size of the filter required is 10 m2 of 
total filter surface area. 
 
Shell-and-Tube Heat Exchanger 
Throughout our process we have three separate shell-and-tube heat exchangers, all of 316L 
stainless steel material of construction. In the bioreactor aeration process, the filtered, 
compressed air is sent through the shell side of the Air Compressor After-Cooler, HE-212, where 
cooling water brings it from 89°C down to 37°C. The cooling water, in turn, is heated from 25°C 
to 30°C before being sent to Tk-801, the Potable Water Tank. In the WFI system, the Purified 
Water Pre-Heater, HE-811, allows for contact between the steam boiler bottoms liquid and 
incoming purified WFI, heating the WFI on the shell side from 22°C to 24.5°C and cooling the 
bottoms from 94.4°C to 50°C. In the WFI Condenser, HE-812, the WFI is preheated even more 
on the tube side from 24.5°C to 106.2°C while a portion of the steam produced in the boiler is 
condensed from 136.1°C to 110°C. Using these changes in temperature for ΔLMTD, heat duty 
provided by Aspen HYSYS, as well as known U values for a stainless steel air-water, water-






KO Drum  
Two knockout drums are present in the process, one before the air compressor and one before 
the steam compressor. Both separators were sized using the guidelines provided by Svrcek and 
Monnery in their article, Design Two-Phase Separators Within the Right Limits [38]. The team 
compared the volume and cost of vertical and horizontal separators with and without demister 
pads. For both knockout drums, it was determined that horizontal orientation without demister 
pads provided the lowest cost while still providing the utility and equipment safety required 
before the compressors. 
 
Steam Boiler 
The steam boiler is the most important item in the WFI system, as it is what takes purified 
water and makes it into water for injection. The unit was modeled in aspen as a heat exchanger 
and a heater in series, since both an electric coil and a steam coil are located in the boiler. The 
combined heat transfer for both, 231 kW, as well as a net delta T of 0°C for the boiled water 
(the boiler is not superheating the steam) was used to size and cost the steam boiler. The steam 




Before being sold to pharmaceutical companies for final formulation into a drug that can be 
sold to patients, it is required that the mAbs in solution be stored frozen for at least one year. 
This storage condition provides a challenge to the facility, as proteins must be handled 
carefully, with respect to ice crystallization fronts during freezing, as well as protein damage 
during freeze-thaw cycles [18]. It has been shown that another concern with freezing is 
production of soluble and insoluble aggregates of proteins in solution if the freezing process is 
uncontrolled or uneven. In order to address these concerns for product quality, it was decided 
that a temperature-controlled Freeze-Thaw Cryovessel, V-613, would be used to freeze the 
product after it has left the last filter. The cryovessel will be bought from Sartorius, specifically 
their Celsius FT100 model which is capable of freezing 100 L of product at a time. The freeze is 
temperature-controlled for 4.5 hours until the 3 cycles per batch of 100 L reach -50°C. 
 
Storage Freezer 
Once frozen, the 12 L bags of product will need to be maintained at a constant temperature for 
at least one year. In order to do this, the team identified laboratory deep-freeze cabinets which 
can hold 792 L of product, or sixty-six 12 L bags. In order to be able to hold an entire year’s 
worth of product, 18 deep-freeze storage cabinets will be bought in order to store and maintain 
the mAb product at -50°C.  
 
CIP 
The CIP system is designed to contain enough of the various cleaning solution to clean the 
entire process one time. Using the CIP heuristics in Table 10, the total amount of each CIP 
solution was calculated. Accounting for a 90% working capacity of the vessels, the vessels sizes 




these vessels are constructed of 316L stainless steel because of its anti-corrosive and sterile 
properties. 
 
EQUIPMENT SPECIFICATION SHEETS 
 
The equipment specification sheets were made for all capital costed equipment. Equipment 
























































EQUIPMENT COST SUMMARY  
 









FIXED CAPITAL INVESTMENT SUMMARY 
In order to predict and calculate economic metrics for our project, we assumed that all fixed 
capital investments were incurred during the year 2019. The project, however, does not begin 
production until halfway through the year 2020. 
 
Roller Bottle Roller and Cell Bag Rocker Tray 
In order to approximate the cost of the Roller Bottle Roller, RB-203, and the Cell Bag Rocker 
Tray, CB-205, quotes from vendor catalogs were obtained [20,21] 
 
Centrifuge 
To estimate the capital investment of the disc-stack centrifuge Cf-304, an automatic disc-stack 
centrifuge with a capacity of 4000 liters per hour was found via a vendor. It was assumed that, 
while Cf-304 only requires 1470 liters per hour, the cost of the centrifuge from the vendor 
would provide a valid estimation and if anything an overestimation of the cost [39]. 
 
Chromatography Columns 
In order to estimate the capital cost of the chromatography columns, the “six-tenths rule,” as 
described in Analysis, Synthesis, and Design of Chemical Processes, was utilized to relate a cost 
estimate for a 90 liter chromatography column to the known required volume of our disparate 
columns [40]. The estimate of $200,000 for a 90 L column was given by Warner and Nochumson 
in Rethinking the Economics of Chromatography from BioPharm International journal [41]. This 
estimate was given in 2003, so the estimate was projected to 2019 dollars utilizing the CEPCI 
before the “six-tenths rule” was applied. 
 
Freeze-Thaw Cryovessel 
In order to approximate the capital investment of the Freeze-Thaw Cryovessel, V-613, a quote 
was obtained via phone call from a vendor for the Sartorius Celsius FT-100 Freeze-Thaw System, 
the system for which our cryovessel is based [42]. 
 
Storage Freezer 
To estimate the cost of the Storage Freezer, Fz-614, a quote from a vendor catalog was 
obtained for one freezer. This was then multiplied by 18 to find the total capital investment in 
freezer storage [43]. 
 
Ultrafilter 
In order to approximate the capital cost of the ultrafilter, a quote direct from vendor was 
obtained via email. The six ultrafilters in series were accounted for to obtain the total capital 
cost of the ultrafilter [19]. 
 
Reverse Osmosis System 
To estimate the fixed capital investment of the Reverse Osmosis System, F-808, the “six-tenths 
rule” [40] was again utilized to relate the cost of a known piece and size of equipment from a 




provided by the vendor is 9200 gallons per day, while the WFI production process requires 
11000 gallons per day of RO water [35]. 
General Equipment Costing 
For all other major pieces of equipment, the Guthrie Method constants and correlations, given 
in Analysis, Synthesis, and Design of Chemical Processes [40], were utilized to calculate the 
“vanilla” purchased cost. A carbon steel material of construction and MAWP of 50 psig is what 
constitutes the vanilla cost for any piece of equipment. A summary of each piece of equipment 
costed from these correlations and the parameter used to do so is provided in Table 18 below. 
 







In order to convert the vanilla purchased costs to installed costs, the purchased costs were 
multiplied by the bare module factors in order to account for infrastructure and installation. 
Material factors also accounted for the use of stainless steel rather than carbon steel for each 
piece of equipment. From the bare module costs, the total module costs were calculated by 
factoring in 3% fees and 15% contingency, a factor of 1.18. All of the correlations and constants 
were created in the year 2001, so the CEPCI was utilized to project the CTM to the current year, 
2019. The pertinent CEPCI figures for the Fixed Capital Investment Estimates are included in 
Table 20 below. 
 
Table 20 : Chemical Engineering Plant Cost Index for Relevant Years 
  
 
The total fixed capital investment for the project is $17.6 million. The 2019 total module costs 




The chromatography column and adsorption column resin, granular activated carbon, and filter 
and membrane cartridges all pose working capital costs to our facility when they are purchased. 
This is because they are not completely used up during the year in which they are purchased, as 
raw materials are, nor are they pieces of equipment that can continue to hold value once they 
have been placed into service. For this reason they cannot be deducted as an operating cost or 
depreciated as a fixed capital cost. We will write off the price we paid for the material at the 
end of the year in which its equipment life has ended. Only then can we realize the full value of 
the equipment in our tax deductions. Table 21 below summarizes the working capital over the 
life of the project. 
 










Environmental, health, and safety (EH&S) considerations are overseen and addressed by a 
process safety management (PSM) system. Good Manufacturing Practices (GMP) for the 
preparation of drug products in the United States are outlined by the FDA in their Code of 
Federal Regulations Title 21 Part 211. The PSM system must adequately cover GMP for the 
organization and personnel, building and facilities, equipment, control of components and drug 
product containers and closures, production and process controls, packaging and labeling 
control, holding and distribution, laboratory controls, records and reports, and returned and 
salvaged drug products [44]. 
  
Occupational Safety 
Occupational safety is considered in this design for the purpose of protecting those who work in 
this facility. A large portion of this safety will come from training. The FDA requires that 
qualified personnel to undergo GMP training on a continuous basis to assure that they are 
familiar with CGMP requirements. Being familiar with training is one of the best ways to 
prevent incidents from occurring. Furthermore, consultants are required to be upheld to the 
same standard as facility employees. This ensures that everyone on the premises knows what is 
expected of them and knows how to handle themselves when working.  Personnel must have 
good sanitation and health habits. This deters the spread and growth of potential pathogens 
that could infect the process. Any health conditions or concerns must be reported in order to 
not jeopardize the product quality.  
 
Both a security measure and process safety measure, only authorized personnel may enter 
certain areas. Proper training is required in many areas of the facility, and anyone without that 
training poses an occupational safety risk to others, themselves, and the process.  
Personal Protective Equipment (PPE) will be held to a high standard during operation. The 
proper protection of someone on site is crucial to their safety. Consequences of improper PPE 
may include skin and eye irritation, chemical burns, respiratory distress and choking, infection 
from foreign pathogens and contamination of the process.  Gloves must be worn at all times in 
the lab. When removed, proper removal technique must be used and the gloves are to be 
disposed of in biohazard waste. Powered air purifying respirators (PAPRs) should be worn in 
media and buffer prep area as a secondary means of exposure control where potent compound 
exposure potential is possible, as indicated by air monitoring data.  
 
Another form of occupational safety is ergonomics. Training on this subject will be included in 
the training program required of employees. For many board operators, ergonomics can play a 
significant role in occupational safety when spending many hours of a shift sitting at a control 
panel. Proper ergonomics will promote good posture and resting positions, this will minimize 





When detailed design is considered, security measures should be taken to guard against 
external threats. Fences, security checkpoints, and random screenings will deter potential 
threats while also putting another layer of protection between the facility and the community.  
 
Product Requirements 
A quality department is responsible for the testing and approval or rejection of components, 
drug product containers, closures, packaging materials, in-process materials, and drug products 
[44]. An adequate number of personnel must be present for the quality department to perform 
its functions. Testing for hazardous biological contaminants will include tests for Retroviruses, 
in vitro assays, and in vivo assays [45]. This testing will occur between The Protein A 
Chromatography Column and viral inactivation tank in order to measure what level of 
contamination must be reduced. Testing will also occur before product freezing in the Freeze-
Thaw Cryovessel to ensure product quality and safety. If there is a rejection by standards at the 
product step, more testing will be conducted after the HIC and IEX Chromatography columns in 
order to identify the step that is not effectively inactivating viral contaminants.  
  
Equipment MOC must not alter the quality or purity of the product. No substances required for 
operation, such as lubricants or coolants, shall come into contact with any process components 
that could alter the quality or purity of the product. This risk is reduced by the use of the 
diaphragm pumps utilizing electric motors. The diaphragm separating the wetted and non-
wetted side separates the process fluid from the rest of the pump housing.  
  
Product must be quarantined until the quality department releases it. Procedures must outline 
that the oldest product must be distributed first and removal procedure if there is a recall of a 
batch of product. This is a procedural safeguard against release of low quality or contaminated 
product to further processing and potentially the larger community.  
  
 Industrial Health 
All pieces of equipment in the process that come into contact with the process materials have a 
method of cleaning or sterilization. A Steam in Place system and a Clean In Place system are 
designed to sterilize and wash any piece of equipment that is not single use. All single use 
equipment is disposed of properly into biohazard waste containers that will be available on site.  
 
Buildings must be maintained in a clean and sanitary condition with adequate lighting and in a 
good state of repair.  Any in-process materials must be properly labeled, stored properly, 
disposed of in a timely and sanitary manner, and have written procedures. 
 
Per FDA regulations, air must be supplied to the building under positive pressure to maintain 
airflow. Also, the quality of air must be high enough by passing the air through high-efficiency 
particulate filters [44]. 
 
The room in which media is prepared must have a method of disinfecting the room so that the 




utilize air filtration systems. These systems include but are not limited to: pre filters and 
particulate matter air filters. This prevents dust recirculation in the facility. Fume hoods will be 
placed over the buffer preparation areas to protect against volatile vapor hazards.  
 
Medical gas containers will be available and on site. They must be portable and self-contained 
to ensure reliability and efficiency in case of emergency situations. This is a layer of protection 
in place to respond to health related incidents involving respiratory distress. On site HSE 




Fugitive air emissions must be identified and mitigated if necessary. The vapors involved in the 
design of this process and their respective hazards to the environment have been summarized 
in Table 22 below. Nitrogen, carbon dioxide, and oxygen are all components of ambient air that 
have no fugitive emissions concerns other than the flammability of oxygen. However, oxygen 
will not be in high enough concentrations to be cause for concern. Ambient air is not 
flammable, so the flammability concern is not a pertinent risk as oxygen concentration will not 
be raised above ambient air concentration in this design. Steam is produced in this process, but 
there are no emission hazards associated with a release of steam to the atmosphere. Aqueous 
hydrochloric acid is utilized throughout the design. This is a volatile chemical and is known to 
have vapor emissions of the acid. HCl vapor is both toxic and a pollutant. A release of this vapor 
would most likely result in a pollutant concern because this vapor is highly soluble in water. This 
could result in large amounts being put into solution with rain water or large bodies of water. 
Acid rain is corrosive to metal structures and buildings, and aqueous HCl is toxic to aquatic 
organisms. 
 
Table 22: In accordance to the Clean Air Act Amendments of 1990, Title I, Clean Air Act 
Amendments of 1990, Title III, Emergency Planning and Community Right-to-Know Act 
 
 
Fume hoods will be incorporated in the buffer preparation area to collect any HCl vapors that 
could evaporate off of the designed HCl solutions used in the process. This actively reduces the 
risk presented by HCl vapors to the environment.  
 
Liquid and solid wastes in this design are treated in the waste process. Two steps are taken to 
ensure sewage feed requirements are met. The first step is the steam injection process 
mentioned in the process description. The purpose of this steam injection step is to kill, 
denature, and inactivate any biological components that could remain in the waste stream prior 









to release into the sewage system. The steam does this by raising the process stream 
temperature above 80 degrees Celsius for over a minute to adequately ensure microbial death 
[46]. The second step is the aqueous HCl addition to the neutralization tank. This step acts to 
lower the caustic pH of the stream into an acceptable range for sewage (5 to 9 pH) and dilute 
the waste even further. Any inorganic components that do not contribute to pH in the waste 
will be diluted to a lower concentration due to this addition of the aqueous solution. 
 
PROCESS SAFETY CONSIDERATIONS 
 
Objective  
In order to reduce the risk of the production process, a detailed safety evaluation was 
performed using various methods to challenge safety concerns from multiple perspectives. Our 
main focus is to identify and mitigate hazards such as: toxicity, flammability, reactivity, 
environmental hazards, and biological hazards. 
  
The overlying goal is to create a process design that is inherently safe with low levels of risk due 
to the design and that safety is less reliant of safety precautions and protective systems. An 
inherently safer design evaluates alternatives and aims to consider all potential hazards. It is 
crucial for this to be done at the preliminary design stage to allow for minimal possible damage 
to the environmental, business, and personnel.  
  
Taking into consideration the inherently safer design, additional safety evaluations are 
performed. A Hazard Identification Summary was created using Risk Rank Matrix. Material 
properties, inventory estimates, and process technology, equipment, & operating conditions 
are evaluated. The Potential consequences summary identifies the potential for equipment 
damage, environmental compliance, loss of life, disruption of other business units, legal/PR, 
and community impact.  
  
This preliminary design is assumed to have appropriate traditional plant safeguards, written 
procedures, mitigation equipment, and the various safety systems including emergency 
shutdown systems. 
  
Inherently Safer Design 
  
When considering how to design an inherently safer process, strategies such as minimization or 
intensification, moderation or attenuation, substitution, and simplification should be evaluated. 






Table 23: Inherently Safer Design Summary 
 
Concept Incorporation in Preliminary Design Hazard Addressed 
Attenuation Vent lines incorporated into bioreactor 
and tank design 
Relieves pressure buildup in 
reactors 
Substitution Using chemically defined media 
instead of serum media 
Facility is animal free 
Minimization Centrifuge and chromatography 
processes utilize multiple cycles per 
batch to minimize process fluid under 
process conditions 
Larger centrifuge size poses a 
larger mechanical hazard. Larger 
chromatography columns process 
larger amounts of hazardous 
materials at one time.  
Minimization Only preparing enough media or 
buffer for one process cycle to 
alleviate unnecessary storage  
Large quantities of hazardous 
materials like acidic or caustic 
buffer preparation material being 
stored for long periods of time.  
Intensification Diafiltration steps after each 
chromatography step reduce 
biological and chemical contaminant 
risks 
Possibility of contaminants making 
it to the end product.  
Attenuation Dilution of all acidic or caustic 
solutions 
Reduces hazard of storage. 
Reduces storage pressure. Reduces 
initial atmospheric concentration if 
a release occurs.  
Simplification The use of disposable units in the seed 
train process. 
It is less difficult to keep sterile 
conditions. It also reduces the 
number of cleaning steps in the 
process.  
Substitution Positive Displacement Diaphragm 
pumps were selected over cheaper 
centrifugal pumps.  
Reduces the hazard of 
contamination of process flow with 
contaminants associated with 
centrifugal pumps in biological 
processes.  
Substitution Materials of construction are 316L (SS) 
instead of carbon steel 
Reduces risk of corrosion and 
surface metal release into solution, 
thus reducing contamination risk.  
 
Hazard Identification and Risk Analysis 
 
Near misses or injuries are typically traced back to the failure to identify hazards that could 
have been anticipated. Hazard identification is commonly sourced from the materials used and 




equipment operating conditions. The source and the hazard are identified in the summary 
Table 23 and interaction matrix in Table 23. 
 
The risk analysis is done using Figure 14. The potential risk is the product of consequences and 
probability. The consequences are based upon health/safety risk, environmental impact, and 
economic impact. Probability is the likelihood of an injury occurring. The hazards are rated by 







Table 24: HSE Hazard Identification Summary 
Source Hazard Risk Rank 
Material 
Properties 
Acids (HCl and eluting) 
Sodium Hydroxide (NaOH)  
Steam 
 












Media Prep Tanks 
Buffer Prep Tanks 
Final Formulation Storage 



























































































Figure 14: Preliminary Design Risk Rank Matrix 
 
Interaction Matrix 
In this process, a variety of chemicals are used for a variety of reasons. Chemical reactivity 
poses a threat to any process that contains chemicals that can mix and react with each other. 
This process contains inherently dangerous and reactive chemicals that can potentially react 
dangerously with each other. Table 25 is an interaction matrix for this design [47]. All of the 
chemical species in the process are included around the outside of the table. The cells inside 
the table describe the interaction between the species on the outside. This is useful to see the 
potential hazards that the process may contain if streams mix. For this process oxygen, 
ammonium sulfate, and hydrochloric acid are the most dangerous materials as they are 
incompatible with most of the other species present. The interaction matrix below contains all 












Potential Consequence Summary 
  
Potential consequences are ranked based upon the immediate impact in Table 26. 
  

















































High None None High None None 
  
Safety Assessment Summary  
1. Potential project termination 
• After considering the aforementioned safety concerns in the hazard analyses, 
none of said concerns have high enough risk levels to warrant a project 
shutdown due to safety concerns.  
 
2. Major concerns requiring significant attention 
• Dust inhalation hazard 
• If the waste line to sewage is out of the pH range requirements, a massive 
amount of materials will be put into the sewage line. Large environmental 
consequences could result in significant fines as well.  
 




• Total employee participation in PSM practices and mindset is vital to maintaining 
a safer work environment. The facility will benefit if one hundred percent of 
employees participate in every required training, go about their work days while 
keeping PSM in mind and maintain good practicing integrity. Training will include 
the initial training as well as refresher training to keep employees up-to-date and 
in compliance with PSM.  
• Process Hazard Analysis (PHA) is an integral part of PSM. They should be 
conducted regularly and identified hazards should be assessed and mitigated in a 
timely manner.  
• Pre-Startup Safety Review (PSSR) for equipment will need to be handled very 
carefully and meticulously. With so many batch style pieces of equipment, PSSRs 
will be used daily. PSSRs will need to be reviewed and updated regularly to avoid 
miscommunication that could result in improper use of process equipment.  
• Hot work will not be conducted on a regular basis in this facility. Typically, it 
should only be required in some instances of maintenance and repair. 
Regardless, hot work permits and procedures should be in place for the times it 
is needed.  
 
4. Specific concerns - RMP related 
• If viral inactivation is not carried out to its fullest extent as designed, potential 
harm to the community end users and large regions could receive ineffective or 
harmful drugs.  
• HCl vapor release to the environment and surrounding communities is a 
significant environmental concern relating to the facilities relationship with the 
surrounding area.  
 
Siting and Layout of Processes and Equipment 
The FDA requires that the building have enough room for cleaning, maintenance, and proper 
operations. Enough space with defined areas must be designed in order to not mix up the 
different components. The layout must also flow in order to minimize contamination.  
 
All chemical compounds used or stored on site must have appropriate labels and Safety Data 
Sheets (SDS) available. This provides a layer of protection against misidentification of materials 
and improper cleaning or response to exposure. Storage of chemicals relevant to this design 
must be categorized and separated based on properties. The following categories of chemicals 
must have their own storage areas: 
 
• Inorganic salts (chlorides and phosphates)  
• Inorganic corrosive bases that are dry (Dry Hydroxides and Carbon)  
• Non-metal corrosive acid (Hydrochloric acid) 
 
These separate storage containers will be dry, flame and tamper proof. Also, it is good practice to 
store all compounds at eye level with labels facing out for ease of identification and 




identification, separation of potentially reactive mixtures, and simplification of spill cleaning 
procedures. Mixtures of compounds that are alike are easier to properly clean than differing 
compound mixtures [48]. 
 
The media preparation equipment will need to be in its own room due to dust hazards and the 
contamination threat it poses. The large vessels used in this area for media preparation will 
have pumps to deliver media to the bioreactors in a separate room.  
 
 
OTHER IMPORTANT CONSIDERATIONS 
 
HAZOP 
The team performed a preliminary design HAZOP in order to account for and assess the 
potential consequences and probability of hazards to personnel and equipment. Safeguards 
and actions to be taken in the event of such a deviation were also considered. This HAZOP is 
detailed in Table 27 below. 
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MANUFACTURING/OPERATION COSTS  
 
Raw Materials 
In order to estimate the annual manufacturing costs of the project facility, it was important to 
summarize the total raw materials costs incurred annually. Raw materials included chemicals 
used for buffer and media preparation, CHO cells, disposable inoculation equipment, freezer 
storage bags, and other miscellaneous chemicals introduced into the process. Table 28 below 
summarizes the total raw materials amounts and costs for the first half-year of the project and 
in every year after that. 
 








 Another major manufacturing cost are the utilities purchased on an annual basis: sewer, 
potable water, and electricity. Sewer costs are $0.05/gallon, potable water costs are 
$0.543/1000 liters, and electricity costs are $0.05/kW-hr. Utility consumption and costs are 
summarized in Tables 11, 12, and 13 in the Utility Requirements section of the report. The total 
utility costs incurred annually is $247,778. 
 
Labor Costs 
Along with utility and raw materials costs, generally the next most significant manufacturing 
cost is the cost of labor. In order to determine labor costs, we first needed to determine the 
total number of operator positions required for the facility at any one point in time. In order to 
estimate this, we utilized the Equipment Module Approach as outlined in Analysis, Synthesis, 




Figure 15: Equipment Module Approach Equation 
 
In the equation, P represents the number of particulate solid handling steps and Nnp represents 
the number of non-particulate processing steps. It was determined that P is equivalent to 40 
while Nnp is 13. However, according to the West Virginia University Department of Chemical 
Engineering, one should set P equal to zero if it is greater than two and now add P to the new 
NOL value [50]. Utilizing this guideline, we determined NOL to be 43.05. Assuming a 24-hour 
operating facility and that 4.5 operators are required for each position, this means there are 
194 operators needed for the new facility. According to the Bureau of Labor Statistics, in the 
Pharmaceuticals and Medicine Manufacturing field, the annual mean wage for a Plant and 
System Operator is $51,280. With this known, we find our annual labor costs to be $9.95 
million. 
 
Other Manufacturing Costs 
Outside of the three main categories of manufacturing costs already discussed, others include 
supervisory labor, lab costs, maintenance and repairs, local taxes and insurance, overhead 
costs, supplies, and administration costs. These other manufacturing costs are summarized with 
raw materials, utilities, and operating labor in Table 29 to give a summary of total 
manufacturing costs for the project. Taking all of these costs into account, the total annual 








Table 29: Manufacturing Costs    






There is not currently a standard market sales price for mAb products. Figure 16 compares the 
revenue per kilogram of production for different mAb derived pharmaceuticals and other 
similar pharmaceuticals. The estimated mAb sales price was determined by averaging these 
values, minus Humira which was an outlier. The estimated sales price for this project is $4.6 
million/kg of mAb. This value is necessary to determine the annual revenue of the project. The 
effects of any error in this estimation are addresses in the following economic analyses. The 
annual revenue for this project is $6.96 billion. 
 
Figure 16: Sales Price of Various mAb Derived Pharmaceuticals  
 
 
DCFROR and NPV Analysis 
In order to evaluate the economic feasibility of the project, the discounted cash flow rate of 
return as well as the net present value were the primary metrics utilized. The following 





Project Life was assumed to be 25 years. All capital expenses are incurred during 2019. 
Production begins during mid-2020 and continues through 2045. NPV and DCFROR are based 
upon this assumed life of the project. 
 
The Minimum Rate of Return was assumed to be 15% for the project. In order for the mAb 
production facility to be economically feasible, the project’s DCFOR would need to be greater 
than 15%. When calculating net present value, this minimum rate of return was also utilized. 
 
Tax Rate for the project is known to be 21%, as specified by the 2017 tax act (Pub. L. No. 115-
97). The 2017 tax act taxes corporation at a flat rate of 21%, down from a previous maximum 
tax rate of 35% [51]. 
 
The MACRS Depreciation Basis for fixed capital investments was determined to be 10 years 
based on IRS Publication 946. The fixed capital investment can be recovered through tax 
deductions by the year 2030.  
 
A cash flow table was constructed in order to analyze and evaluate the economic attractiveness 
of the mAb production facility project. An escalation rate of 2% was assumed and used to 
escalate all costs and revenues throughout the life of the project. The washout assumption was 
determined to be not valid, as the amount that costs and revenues increased was not 
equivalent.  
 
We determined that the NPV of the project is $31.4 billion, and the current dollars DCFROR is 
6350%. The NPV is greater than zero and the DCFROR is greater than the minimum DCFROR of 
15%, thus the project is determined to be economically attractive. 
 
Payback Period Analysis 
Based off the cash flow table, the discounted payback period for the project was determined to 
0.0185 years or 6.78 days. This means that as long as the facility operates for one week then it 
will make back all of its initial capital investment. However, it is known that it will actually take 
51 days for the first batch of mAb to be produced. Only after this period will there be any 
product with which to create revenue. Thus, a more realistic payback period on the initial 
capital investment for the project is 51 days. 
 
Optimization Analysis 
A major consideration the preliminary design team made during the course of the design 
formulation was whether to buy Water for Injection for the process or to design a system to 
purify potable water and make our own WFI. Both designs were performed and an economic 
analysis on both options was performed for comparison. The comparison of buying and making 







Table 30: Economic Comparison between Buying and Making WFI 
 
 
One can see that the economic parameters when comparing the two options do not paint a 
simple black and white picture. If the facility buys its own WFI, this imposes a greater capital 
investment on the project as expected, due to the additional equipment required to purify the 
potable water. However, the annual operating costs are significantly increased if it buys its WFI, 
due to the additional raw material costs. The DCFROR of buying the WFI is over 1000 
percentage points greater than when making your own WFI, but the NPV when making WFI is 
almost $50 million greater than buying it over the course of the 25-year project. In order to 
determine definitively the best option, the team performed an incremental analysis on the 
scenarios. Subtracting the buy option from the make option, one can see that the NPV of $48 
million is still greater than zero and the DCFROR of 90% is greater than the minimum DCFROR if 
15%. Thus, it is confirmed that making WFI is a more economically attractive option than buying 
it. 
 
A cash flow table summarizing the revenues and expenses incurred during every year of the 












Single Variable Sensitivity Analysis 
Single variable sensitivity analysis is a qualitative economic evaluation of risk, performed by 
altering economic variables individually to see how the discounted cash flow rate of return 
(DCFROR) will be react. The analysis evaluates the parameter uncertainty and how it correlates 
to the project’s viability. The analysis does not account for probability or variation so the 
analysis was done for years 2-25. 
 
The uncertainty of the sales price ($/kg), annual profit, raw material or feed cost, and capital 
cost are analyzed. These parameters cause the most economic uncertainty, best predict the 
viability of the project, and account for the largest variability in the project’s overall economics. 
The project life is assumed to be 25 years, and the capital cost estimates are preliminary 
estimations. The analysis will indicate where future focus or investments are best utilized. 
 
The economic analysis provides a DCFROR of 6345.8%. The percent change in predictions is a 
form of statistical analysis that is used to find the variation in the parameters and degree of 
confidence. The sales price range of confidence is ± 20% and the fixed capital cost ranges from 
and -20% to 50%. Annual profit is ± 40% and raw materials ranges from -10% to 30%. A 
summary of the sensitivity analysis of the four parameters are shown throughout Tables 32-36. 
 
In the sensitivity analysis, some assumptions are made. The key assumptions is that the isolated 
variable is the only value that changes and all other factors are constant. Another assumption is 
that production remains constant and therefore profit is constant (except when the sales price 










Table 32: Sales Price Calculations for 
Tornado Chart 
 
Table 33: Fixed Capital Investment Calculations 
for Tornado Chart 
 
Table 34: Annual Profit Calculations for 
Tornado Chart 
 
Table 35: Raw Material Investment Calculations 










Figure 17: Tornado chart representing parameter sensitivities 
 
The tornado chart shown above in Figure 17 displays the DCFROR variation based off the 
calculated DCFROR of 6345.8%. The single most sensitive variable was the sales price as the 
profit is based on low titers sold for high dollars. Even a small change in sales price with 
drastically impact the profit margin for any given year. The next highest was the fixed capital 
investment. This impact is due to the cost being incurred at the beginning of the project life as 
this has a significant effect on the overall profit. This is a significant variable in the project's 
profitability and is the leading factor in the project’s long-term success. The annual profit is not 
a very sensitive variable because the annual profit is such a large number that fluctuation has a 
small effect on the margins. The cost of the raw materials has a minimal effect on the viability 
of the project. The cost of the raw material is minuscule in comparison to the project’s annual 




Break-even analysis was the final economic analysis that was performed for the project. This 
analysis is used to determine the value of some variable at which the project becomes 
profitable. For this project, the break-even sales price of mAb was determined by varying the 
sales price of mAb ($/kg) until the NPV of the project equals 0. The break-even price was 
Table 36: Minimum and Maximum Percent 





calculated to be $28,889.25/kg of mAb. As long as the sales price of mAb is above that value, 
the project will be economically attractive. This value is especially important if this production 
facility is ever contracted out to other companies. If that is the case, the other companies need 
to pay at least this price per kg of mAb for the process to be profitable.  
CONCLUSIONS AND RECOMMENDATIONS 
 
Conclusions 
The proposed design in this report meets the technical requirements for the manufacturing 
facility proposed by The Company management. Both the required annual production and 
production titer were fulfilled while also meeting the other specifications set forth in the 
project statement. The design is capable of producing 1514 kg/yr of mAb (29.6 kg/batch) at a 
titer of 2 g/L with a 7 day cycle time. Included in the design are a continuous water for injection 
production system, a full-scale SIP and CIP skid, waste treatment and disposal processes, and an 
air compression system—everything that is necessary for immediate full-scale production. 
Facility production can be scaled up by several methods including staggering more units to 
decrease the cycle time and harvesting the cells from each seed train step at a higher density 
(increasing the time of each seed train step) as the demand for mAb products grow. 
  
The NPV of the project is $31.4 billion, and the current dollars DCFROR is 6350%. The total 
capital cost ($17.6 million) and annual operating cost ($34.9 million) are significantly smaller 
than the annual revenue ($6.96 billion). The payback period is one batch, approximately 51 
days, and the break-even sales price is just under $29,000/kg mAb while the average sales price 
is $4.6 million/kg mAb. Taking all of these economic factors into consideration, this project is 
very economically attractive. 
  
Analyzing the single variable sensitivity analysis, the mAb sales price and fixed capital 
investment have the greatest impact on the DCFROR. The analysis also reveals that even under 
less than optimal conditions, the project is still economically attractive. Incremental analysis 
comparing making WFI to purchasing WFI indicates that the project is economically attractive 
under with either method, but making WFI is the more attractive option. 
  
Safety is of the utmost importance in this process because of the biological cultures that are 
worked with and because the product is being used in pharmaceuticals. The process is designed 
with a SIP and CIP system that maintains sterile conditions within each process unit. Only water 
for injection is used in the process and all the air that enters into the process is filtered prior to 
entering the process. The product stream is virally inactivated in two orthogonal steps and the 
waste stream is heated with steam and neutralized with acid to make it safe to enter the 
sewage system. The design was optimized to be inherently safer by preparing hazardous 
chemicals immediately prior to their use and by operating the centrifuge and chromatography 
columns in cycles. Both of these design decisions limit the hazard associated with moving and 





Overall, the project is both economically attractive and technically feasible. Thus, The Company 
management should move forward with the proposed project. 
 
Recommendations  
• Proceed with the detailed design of this process. 
• Explore further reducing the cycle time by adding more staggered equipment. The 
additional capital costs will be outweighed by the increased revenue. 
• Scale up the size of the WFI and SIP/CIP systems as the process is scaled up. 
• Test BalanCD Growth A and Feed 4 media with CHO cells to determine the optimal 
inoculation and harvest densities and other optimal seed train conditions. 
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Appendix A: Economics 
 
Table A.1 : Media Prep Vessel 1 Costing 
 
 









CBM=Cp0(B1+B2*Fm*Fp) Impeller Diameter (m) 0.625
*vertical for compressors Flat Paddle Power Number 1.8
*L/D= 2.5 to 5 Liquid Density (kg/m^3) 996
*should be no less than 10 time the liquid volume passing per minute RPS 1.6667
Without Demister
Min Vessel Volume (m3) Pressure (barg) Diameter (m) Power [kW]
4 1.52 1.25 0.792 0.395798588
Fp B1 B2
0.794641763 2.25 1.82
min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $6,402.56
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019




K1 (Table A.1) K2 K3 Cp0
3.8511 0.7009 -0.0003 $6,025.02
Fbm (Table A.7) Cbm CTM CTM 2019
1.38 $8,314.53 9,811.14$                     16,245.74$                    
Media Prep Vessel 1
CBM=Cp0(B1+B2*Fm*Fp) Impeller Diameter (m) 0.6
*vertical for compressors Flat Paddle Power Number 1.8
*L/D= 2.5 to 5 Liquid Density (kg/m^3) 1024
*should be no less than 10 time the liquid volume passing per minute RPS 1.6667
Without Demister
Min Vessel Volume (m3) Pressure (barg) Diameter (m) Power [kW]
20 1.52 1.2 0.664 0.331795907
Fp B1 B2
0.782856092 2.25 1.82
min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $18,310.73
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019




K1 (Table A.1) K2 K3 Cp0
3.8511 0.7009 -0.0003 $5,324.28
Fbm (Table A.7) Cbm CTM CTM 2019
1.38 $7,347.51 8,670.06$                     14,356.28$                    




Table A.3 : Production Bioreactor Feed Media Prep Vessel Costing 
 
 








CBM=Cp0(B1+B2*Fm*Fp) Impeller Diameter (m) 0.625
*vertical for compressors Flat Paddle Power Number 1.8
*L/D= 2.5 to 5 Liquid Density (kg/m^3) 996
*should be no less than 10 time the liquid volume passing per minute RPS 1.6667
Without Demister
Min Vessel Volume (m3) Pressure (barg) Diameter (m) Power [kW]
4.5 1.52 1.25 0.792 0.395798588
Fp B1 B2
0.794641763 2.25 1.82
min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $6,857.91
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019




K1 (Table A.1) K2 K3 Cp0
3.8511 0.7009 -0.0003 $6,025.02
Fbm (Table A.7) Cbm CTM CTM 2019
1.38 $8,314.53 9,811.14$                     16,245.74$                    
Feed Media Prep Vessel (2X)
batches per yr OPERATING COSTS TOTAL 8,197.53$    
51
T-Flask 1
$$ # in shipment $$ each Volume (100mL) $$ per 2020 $/2021+
398.9 200 1.99$                 15-38 35.90$            101.72$       
https://www.sigmaaldrich.com/catalog/product/SIGMA/C6481?lang=en&region=US&cm_sp=Insite-_-prodRecCold_xviews-_-prodRecCold5-3
T-Flask 2
$$ # in shipment $$ each Volume (100mL) $$ per yr
427.1 120 3.56$                 35-52.5 64.07$            181.52$       
https://www.sigmaaldrich.com/catalog/product/SIGMA/C7106?lang=en&region=US&cm_sp=Insite-_-prodRecCold_xviews-_-prodRecCold5-2
Roller Bottle 
$$ # in shipment $$ each Volume (100mL) $$ per yr
858.2 44 19.50$               1L 351.08$          994.73$       
https://www.sigmaaldrich.com/labware/labware-products.html?TablePage=9577881
Cell Bag  
$$ # in shipment $$ each Volume (100L) $$ per yr









































CBM=Cp0*Fbm Impeller Diameter (m) 0.026
Volume [m^3] Power Number 1.8
0.25 From Excel Calc Diameter (m) Liquid Density (kg/m^3) 1101
10<P<100 barg 0.052 RPS 0.083333
Jacketed Agitated Reactor 1 Min:0.1 Max:35[m^3] Power [kW]
K1 (Table A.1) K2 K3 Cp0 0.0
4.1052 0.532 -0.0005 6,091.48$                   
Material Fbm (Table A.7) CBM CTM CTM 2019
SS 4 24,365.92$    28,751.79$                 47,608.53$       
CBM=Cp0*Fbm Impeller Diameter (m) 0.75
Volume [m^3] Power Number 1.8
5 From Excel Calc Diameter (m) Liquid Density (kg/m^3) 1101
10<P<100 barg 1.5 RPS 0.0833333
Jacked Agitated Reactor 2 Min:0.1 Max:35[m^3] Power [kW]
K1 (Table A.1) K2 K3 Cp0 0.00027
4.1052 0.532 -0.0005 29,978.35$                 
Material Fbm (Table A.7) CBM CTM CTM 2019
SS 4 119,913.41$  141,497.82$               234,298.58$     
Seed Culture Bioreactor 1 (R-207)






























reciprocating) Min:450 Max:3000 C1,2,3=0 0.95
K1 (Table A.1) K2 K3 Cp0 Chosen CTM
2.2897 1.3604 -0.1027 $10,776.48 210,083.33$ 
Centrifugal
Material ID # FBM (A.6/A.19) CBM CTM (2001) CTM 2019
SS 2 6.7 $72,202.43 $85,198.87 141,076.19$ 
Axial
Material ID # FBM (A.6/A.19) CBM CTM (2001) CTM 2019
SS 5 8 $86,211.86 $101,730.00 168,449.19$ 
Reciprocating
Material ID # FBM (A.6/A.19) CBM CTM (2001) CTM 2019
SS 11 7 $75,435.38 $89,013.75 147,393.04$ 
Rotary Min:18 Max:950
K1 (Table A.1) K2 K3 Cp0
5.0355 -1.8002 0.8253 $14,216.97
Material ID # FBM (A.6/A.19) CBM CTM (2001) CTM 2019
SS 8 5 $71,084.86 $83,880.14 138,892.57$ 
CBM=Cp0*FBM
Drive
Material ID # (Table A.6) Fbm (Fig A.19) K1 (Table A.1) K2 K3
Electric-totally enclosed 17 3.5 1.956 1.7142 -0.2282
Cp0 CBM limits [kW] CTM CTM 2019





Table A.7 : Air Compressor Knock Out Drum Costing 
 
 
Table A.8 : Water Pre-Heater Costing 
 
 
Table A.9 : Air filter Costing 
 
 
CBM=Cp0(B1+B2*Fm*Fp)*L/D= 2.5 to 5
*vertical for compressors *should be no less than 10 time the liquid volume passing per minute
Without Demister




min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $1,259.01
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019
SS 20 3.1 $6,642.94 $7,838.67 12,979.63$   
Horizontal Process Vessel
B1 B2
1.49 1.52 min=.3, max = 520 m3vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.5565 0.3776 0.0905 $1,667.53
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019
SS 20 3.1 $6,699.27 7,905.13$     13,089.68$   
Air Compressor KO Drum
CBM=Cp0(B1+B2*Fm*Fp) limits:5-140 barg
Area (m^2) Op Pressure [barg] Design Pressure [barg]C1 C2 C3
77.17363222 62.058 62.058 0.03881 -0.11272 0.08183
limits:10-1000
Fp B1 B2 K1 K2 K3 Cp0
1 1.63 1.66 4.1884 -0.2503 0.1974 26,254.98 
Heat Exchanger (tube&shell) (U-tube)
Material ID # (Table A.3) Fm (Fig A.18) CBM CTM CTM 2019
SS-shell/SS-Tube 5 2.8 164,828.78   $194,497.96 322,058.62$ 
35-70 
Q [Btu/hr] U [Btu/ft^2*hrF] T1 (lnlet tube) T2 (outlet tube)t1 (inlet shell) t2 (outlet shell)DelTlm [F] A (ft^2) A (m^2)
7.61E+04 2 77 86 192.5 98.6 53.21 714.5706687 77.173632
Purified Water Pre-Heater (HE-811)
Area (m^2) C1 C2 C3
10 0.03881 -0.11272 0.08183
limits:10-1000
Fbm K1 K2 K3 Cp0 Cbm CTM
1.65 3.2107 0.7597 0.0027 9,399.40   15,509.01     18,300.63 




Table A.10 : Production Bioreactor Costing 
 
 
Table A.11: Production Bioreactor Surge Tank Costing 
 
 
Table A.12 : Dead-End Filter Costing 
 
CBM=Cp0*Fbm Impeller Diameter (m) 1.2315
Volume [m^3] Power Number 1.8
30 Diameter Liquid Density (kg/m^3) 1000
10<P<100 barg 2.463 RPS 0.0833333
Fermenter Reactor Min:0.1 Max:35[m^3] Power [kW]
K1 (Table A.1) K2 K3 Cp0 0.00295
4.1052 0.532 -0.0005 77613.55279
Material Fbm (Table A.7) CBM CTM CTM 2019
SS 4 310,454.21$  366,335.97$                 606,595.88$     
Production Bioreactor (R-301A/B)
CBM=Cp0(B1+B2*Fm*Fp) *L/D= 2.5 to 5
*vertical for compressors *should be no less than 10 time the liquid volume passing per minute
Without Demister




min=.1, max = 628 m3vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $23,197.38
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019
SS 20 3.1 $188,589.13 $222,535.17 368,483.92$     
Horizontal Process Vessel
B1 B2
1.49 1.52 min=.3, max = 520 m3vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.5565 0.3776 0.0905 $19,385.59
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019
SS 20 3.1 $124,078.76 146,412.93$     242,437.24$     
Production Bioreactor Surge Tank (Tk-303)
CBM=Cp0*Fbm
Area [m^2] SuperPro
230 810,000.00$  
10<P<100 barg
Deadend Plate and Frame Filter Min:0.5 Max:80[m^2]
K1 (Table A.1) K2 K3 Cp0
4.28 0.352 0.0714 320022.23
Material Fbm (Table A.7) CBM CTM CTM 2019
SS 1.8 576,040.01$  679,727.21$                 1,125,523.46$  




Table A.13 : Centrifuge Surge Tank Costing 
 
 
















CBM=Cp0(B1+B2*Fm*Fp) *L/D= 2.5 to 5
*vertical for compressors *should be no less than 10 time the liquid volume passing per minute
Without Demister




min=.1, max = 628 m3vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $21,590.42
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019
SS 20 3.1 $2,929,504.17 $3,456,814.92 5,723,952.48$  
Horizontal Process Vessel
B1 B2
1.49 1.52 min=.3, max = 520 m3vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.5565 0.3776 0.0905 $18,248.22
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019
SS 20 3.1 $114,772.18 135,431.17$     224,253.13$     
Centrifuge Surge Tank (Tk-307)
Automatic Disc Stack Solid Bowl 
Centrifuge
$$ for Unit






Table A.15 : Centrifuge Costing 2 
 
 















1 Super pro doesn’t have an area…….
10<P<100 barg Energy/cycle 95.6128
Solid Bowl Centrifuge w/o motor Min:0.3 Max:2 [m] Energy/Batch 382.4512 kW-h
K1 (Table A.1) K2 K3 Cp0
4.9697 1.1689 0.0038 93260.98542
Material Fbm (Table A.7) CBM CTM CTM 2019
SS 1.27 118,441.45$         139,760.91$               
CBM=Cp0*FBM
Drive
Material ID # (Table A.6) Fbm (Fig A.19) K1 (Table A.1) K2 K3 Cp0 CBM limits [kW] CTM
Gas Turbine 13 1.5 -21.7702 13.2175 -1.5279 1.69746E-22 0.00$                     7500-23000 0.00$              
Intern. Comb. Engine 14 1.5 2.7635 0.8574 -0.0098 580.0961725 870.14$                 10-10,000 1,026.77$      
Steam Engine 15 1.5 2.6259 1.4398 -0.1776 422.5713024 633.86$                 70-7500 747.95$          
Electric-explosion-proof 16 3.5 2.4604 1.4191 -0.1798 288.6689018 1,010.34$              75-2600 1,192.20$      
Electric-totally enclosed 17 3.5 1.956 1.7142 -0.2282 90.36494737 316.28$                 75-2600 373.21$          
Electric-open/drip-proof 18 2 2.9508 1.0688 -0.1315 892.8941961 1,785.79$              75-2600 2,107.23$      
https://www.alibaba.com/product-detail/Automatic-Disc-Stack-Solid-Bowl-Centrifuge_60830647396.html?spm=a2700.7724857.normalList.32.17523744M489M2
CBM=Cp0(B1+B2*Fm*Fp) Impeller Diameter (m) 0.625
*vertical for compressors Flat Paddle Power Number 1.8
*L/D= 2.5 to 5 Liquid Density (kg/m^3) 1002.3
*should be no less than 10 time the liquid volume passing per minute RPS 1.6667
Without Demister
Min Vessel Volume (m3) Pressure (barg) Diameter (m) Power [kW]
3 1.52 1.25 0.797 0.39830213
Fp B1 B2
0.794641763 2.25 1.82
min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $5,442.99
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019




K1 (Table A.1) K2 K3 Cp0
3.8511 0.7009 -0.0003 $6,051.71
Fbm (Table A.7) Cbm CTM CTM 2019
1.38 $8,351.36 9,854.60$                     16,317.70$                    




Table A.17 : Protein A Buffer Prep Vessel 2 Costing 
 
 












CBM=Cp0(B1+B2*Fm*Fp) Impeller Diameter (m) 0.75
*vertical for compressors Flat Paddle Power Number 1.8
*L/D= 2.5 to 5 Liquid Density (kg/m^3) 999
*should be no less than 10 time the liquid volume passing per minute RPS 1.6667
Without Demister
Min Vessel Volume (m3) Pressure (barg) Diameter (m) Power [kW]
5 1.52 1.5 1.976 0.98784003
Fp B1 B2
0.853570115 2.25 1.82
min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $7,300.61
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019




K1 (Table A.1) K2 K3 Cp0
3.8511 0.7009 -0.0003 $11,437.77
Fbm (Table A.7) Cbm CTM CTM 2019
1.38 $15,784.13 18,625.27$                   30,840.58$                    
Protein A Buffer Prep Vessel 2 (V-402)
CBM=Cp0(B1+B2*Fm*Fp) Impeller Diameter (m) 0.6
*vertical for compressors Flat Paddle Power Number 1.8
*L/D= 2.5 to 5 Liquid Density (kg/m^3) 995
*should be no less than 10 time the liquid volume passing per minute RPS 1.6667
Without Demister
Min Vessel Volume (m3) Pressure (barg) Diameter (m) Power [kW]
10 1.52 1.2 0.645 0.32239934
Fp B1 B2
0.782856092 2.25 1.82
min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $11,305.77
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019




K1 (Table A.1) K2 K3 Cp0
3.8511 0.7009 -0.0003 $5,218.13
Fbm (Table A.7) Cbm CTM CTM 2019
1.38 $7,201.01 8,497.19$                     14,070.04$                    




Table A.19 : Protein A Buffer Prep Vessel 4 Costing 
 
 
Table A.20 : Protein A Column Costing 
 
 




CBM=Cp0(B1+B2*Fm*Fp) Impeller Diameter (m) 0.5
*vertical for compressors Flat Paddle Power Number 1.8
*L/D= 2.5 to 5 Liquid Density (kg/m^3) 1108
*should be no less than 10 time the liquid volume passing per minute RPS 1.6667
Without Demister
Min Vessel Volume (m3) Pressure (barg) Diameter (m) Power [kW]
5 1.52 1 0.289 0.14427949
Fp B1 B2
0.73571341 2.25 1.82
min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $7,300.61
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019




K1 (Table A.1) K2 K3 Cp0
3.8511 0.7009 -0.0003 $2,969.55
Fbm (Table A.7) Cbm CTM CTM 2019
1.38 $4,097.98 4,835.62$                     8,007.04$                      
Protein A Buffer Prep Vessel 4 (V-404)
Published Price
Volume [L] $$
90 200,000.00$                
Estimated Price 6/10th Rule
Volume [L] CTM 2003 CTM 2019






Deadend Plate and Frame Filter Min:0.5 Max:80[m^2]
K1 (Table A.1) K2 K3 Cp0
4.2756 0.352 0.0714 159985.5403
Material Fbm (Table A.7) CBM CTM CTM 2019
SS 1.8 287,973.97$  339,809.29$  562,671.78$                  




Table A.22 : Viral Inactivation Vessel Costing 
 
 
Table A.23 : Diafiltration Flush Tank 1 Costing 
 
 
CBM=Cp0(B1+B2*Fm*Fp) *L/D= 2.5 to 5 Impeller Diameter (m) 0.5
*vertical for compressors *should be no less than 10 time the liquid volume passing per minutePower Number 1.8
Without Demister Liquid Density (kg/m^3) 995
RPS 1.6667
Min Vessel Volume (m3) Pressure (barg) Diameter (m) Power [kW] Flat Paddle
2 1.52 1 0.259 0.129565065
Fp B1 B2
0.73571341 2.25 1.82
min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $4,386.77
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019




K1 (Table A.1) K2 K3 Cp0
3.8511 0.7009 -0.0003 $11,536.25
Fbm (Table A.7) Cbm CTM CTM 2019
1.38 $15,920.03 18,785.63$    31,106.11$    
Viral Inactivation Vessel (V-408)
CBM=Cp0(B1+B2*Fm*Fp) *L/D= 2.5 to 5
*vertical for compressors *should be no less than 10 time the liquid volume passing per minute
Without Demister




min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $5,442.99
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019
SS 20 3.1 $34,840.04 $41,111.25 68,073.88$    
Horizontal Process Vessel
B1 B2
1.49 1.52 min=.3, max = 520 m3vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.5565 0.3776 0.0905 $5,718.25
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019
SS 20 3.1 $28,343.52 33,445.36$                    55,380.36$    




Table A.24 : Dead End Filter 3 Costing 
 
 
Table A.25 : Viral Inactivation Surge Tank Costing 
 
 




80 45,000.00$    
10<P<100 barg
Deadend Plate and Frame Filter Min:0.5 Max:80[m^2]
K1 (Table A.1) K2 K3 Cp0
4.2756 0.352 0.0714 159985.5403
Material Fbm (Table A.7) CBM CTM CTM 2019
SS 1.8 287,973.97$  339,809.29$  562,671.78$                  
Dead-End Fliter 3 (F-413)
CBM=Cp0(B1+B2*Fm*Fp) *L/D= 2.5 to 5
*vertical for compressors *should be no less than 10 time the liquid volume passing per minute
Without Demister




min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $2,355.70
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019
SS 20 3.1 $13,512.19 $15,944.38 26,401.44$    
Horizontal Process Vessel
B1 B2
1.49 1.52 min=.3, max = 520 m3vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.5565 0.3776 0.0905 $2,825.09
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019
SS 20 3.1 $12,434.18 14,672.33$                    24,295.12$    
Viral Inactivation Surge Tank (Tk-414)
$$ Per Unit (14 m^2)
26,417.00$                                 
# of Units $$





Table A.27 : IEX Buffer Prep Vessel 1 Costing 
 












CBM=Cp0(B1+B2*Fm*Fp) Impeller Diameter (m) 0.5
*vertical for compressors Flat Paddle Power Number 1.8
*L/D= 2.5 to 5 Liquid Density (kg/m^3) 999.5
*should be no less than 10 time the liquid volume passing per minute RPS 1.6667
Without Demister
Min Vessel Volume (m3) Pressure (barg) Diameter (m) Power [kW]
2 1.52 1 0.260 0.130151
Fp B1 B2
0.73571341 2.25 1.82
min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $4,386.77
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019




K1 (Table A.1) K2 K3 Cp0
3.8511 0.7009 -0.0003 $2,762.52
Fbm (Table A.7) Cbm CTM CTM 2019
1.38 $3,812.28 4,498.49$                     7,448.81$                      
IEX Buffer Prep Vessel 1 (V-501)
CBM=Cp0(B1+B2*Fm*Fp) Impeller Diameter (m) 0.5
*vertical for compressors Flat Paddle Power Number 1.8
*L/D= 2.5 to 5 Liquid Density (kg/m^3) 1004
*should be no less than 10 time the liquid volume passing per minute RPS 1.6667
Without Demister
Min Vessel Volume (m3) Pressure (barg) Diameter (m) Power [kW]
3 1.52 1 0.261 0.130737
Fp B1 B2
0.73571341 2.25 1.82
min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $5,442.99
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019




K1 (Table A.1) K2 K3 Cp0
3.8511 0.7009 -0.0003 $2,771.24
Fbm (Table A.7) Cbm CTM CTM 2019
1.38 $3,824.31 4,512.68$                     7,472.31$                      




Table A.29 : IEX Buffer Prep Vessel 3 Costing 
 
 












CBM=Cp0(B1+B2*Fm*Fp) Impeller Diameter (m) 0.625
*vertical for compressors Flat Paddle Power Number 1.8
*L/D= 2.5 to 5 Liquid Density (kg/m^3) 1026
*should be no less than 10 time the liquid volume passing per minute RPS 1.6667
Without Demister
Min Vessel Volume (m3) Pressure (barg) Diameter (m) Power [kW]
5.5 1.52 1.25 0.815 0.4077202
Fp B1 B2
0.794641763 2.25 1.82
min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $7,732.55
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019




K1 (Table A.1) K2 K3 Cp0
3.8511 0.7009 -0.0003 $6,151.66
Fbm (Table A.7) Cbm CTM CTM 2019
1.38 $8,489.29 10,017.37$                   16,587.21$                    
IEX Buffer Prep Vessel 3 (V-503)
CBM=Cp0(B1+B2*Fm*Fp) Impeller Diameter (m) 0.5
*vertical for compressors Flat Paddle Power Number 1.8
*L/D= 2.5 to 5 Liquid Density (kg/m^3) 1023
*should be no less than 10 time the liquid volume passing per minute RPS 1.6667
Without Demister
Min Vessel Volume (m3) Pressure (barg) Diameter (m) Power [kW]
2.75 1.52 1 0.266 0.1332111
Fp B1 B2
0.73571341 2.25 1.82
min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $5,190.04
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019




K1 (Table A.1) K2 K3 Cp0
3.8511 0.7009 -0.0003 $2,807.91
Fbm (Table A.7) Cbm CTM CTM 2019
1.38 $3,874.92 4,572.40$                     7,571.19$                      




Table A.31 : IEX Buffer Prep Vessel 5 Costing 
 
 




















CBM=Cp0(B1+B2*Fm*Fp) Impeller Diameter (m) 0.375
*vertical for compressors Flat Paddle Power Number 1.8
*L/D= 2.5 to 5 Liquid Density (kg/m^3) 1004
*should be no less than 10 time the liquid volume passing per minute RPS 1.6667
Without Demister
Min Vessel Volume (m3) Pressure (barg) Diameter (m) Power [kW]
1.75 1.52 0.75 0.062049011 0.0310245
Fp B1 B2
0.676785058 2.25 1.82
min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $4,099.65
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019




K1 (Table A.1) K2 K3 Cp0
3.8511 0.7009 -0.0003 $1,010.39
Fbm (Table A.7) Cbm CTM CTM 2019
1.38 $1,394.34 1,645.33$                     2,724.40$                      
IEX Buffer Prep Vessel 5 (V-505)
Published Price SuperPro
Volume [L] $$ $$ 2019
90 200,000.00$                635,000.00$                 
Estimated Price 6/10th Rule
Volume [L] CTM 2003 CTM 2019
250 369,188.78$                611,319.69$                 




Table A.33 : Ammonium Sulfate Vessel Costing 
 
 








CBM=Cp0(B1+B2*Fm*Fp) *L/D= 2.5 to 5 Impeller Diameter (m) 0.375
*vertical for compressors *should be no less than 10 time the liquid volume passing per minute Power Number 1.8
Without Demister Liquid Density (kg/m^3) 1066.57
RPS 1.6667
Min Vessel Volume (m3) Pressure (barg) Diameter (m) Power [kW] Flat Paddle
1.25 1.52 0.75 0.066 0.032957975
Fp B1 B2
0.676785058 2.25 1.82
min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $3,482.35
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019




K1 (Table A.1) K2 K3 Cp0
3.8511 0.7009 -0.0003 $1,054.17
Fbm (Table A.7) Cbm CTM CTM 2019
1.38 $1,454.76 1,716.62$                     2,842.45$                     
Amm. Sulfate Vessel (V-508)
CBM=Cp0(B1+B2*Fm*Fp) *L/D= 2.5 to 5
*vertical for compressors *should be no less than 10 time the liquid volume passing per minute
Without Demister




min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $4,663.10
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019
SS 20 3.1 $29,848.03 $35,220.67 58,320.01$    
Horizontal Process Vessel
B1 B2
1.49 1.52 min=.3, max = 520 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.5565 0.3776 0.0905 $5,020.06
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019
SS 20 3.1 $24,882.85 29,361.76$                    48,618.55$    




Table A.35 : Diafilter 2 Costing 
 
 
Table A.36 : HIC Buffer Prep Vessel 1 Costing 
 
 
Table A.37 : HIC Buffer Prep Vessel 2 Costing 
 
$$ Per Unit (14 m^2)
26,417.00$                                 
# of Units $$
2 52,834.00$                  
Diafilter 2 (F-411)
CBM=Cp0(B1+B2*Fm*Fp) Impeller Diameter (m) 0.5
*vertical for compressors Flat Paddle Power Number 1.8
*L/D= 2.5 to 5 Liquid Density (kg/m^3) 1101
*should be no less than 10 time the liquid volume passing per minute RPS 1.6667
Without Demister
Min Vessel Volume (m3) Pressure (barg) Diameter (m) Power [kW]
2.25 1.52 1 0.287 0.143368
Fp B1 B2
0.736 2.25 1.82
min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $4,663.10
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019




K1 (Table A.1) K2 K3 Cp0
3.8511 0.7009 -0.0003 $2,956.38
Fbm (Table A.7) Cbm CTM CTM 2019
1.38 $4,079.81 4,814.18$                     7,971.53$                      
HIC Buffer Prep Vessel 1 (V-601)
CBM=Cp0(B1+B2*Fm*Fp) Impeller Diameter (m) 0.625
*vertical for compressors Flat Paddle Power Number 1.8
*L/D= 2.5 to 5 Liquid Density (kg/m^3) 1047
*should be no less than 10 time the liquid volume passing per minute RPS 1.6667
Without Demister
Min Vessel Volume (m3) Pressure (barg) Diameter (m) Power [kW]
3.5 1.52 1.25 0.832 0.4160654
Fp B1 B2
0.795 2.25 1.82
min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $5,932.07
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019




K1 (Table A.1) K2 K3 Cp0
3.8511 0.7009 -0.0003 $6,239.65
Fbm (Table A.7) Cbm CTM CTM 2019
1.38 $8,610.72 10,160.65$                   16,824.47$                    





Table A.38 : HIC Buffer Prep Vessel 3 Costing 
 
 











CBM=Cp0(B1+B2*Fm*Fp) Impeller Diameter (m) 0.75
*vertical for compressors Flat Paddle Power Number 1.8
*L/D= 2.5 to 5 Liquid Density (kg/m^3) 1015
*should be no less than 10 time the liquid volume passing per minute RPS 1.6667
Without Demister
Min Vessel Volume (m3) Pressure (barg) Diameter (m) Power [kW]
7 1.52 1.5 2.007 1.0036613
Fp B1 B2
0.853570115 2.25 1.82
min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $8,976.99
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019




K1 (Table A.1) K2 K3 Cp0
3.8511 0.7009 -0.0003 $11,565.83
Fbm (Table A.7) Cbm CTM CTM 2019
1.38 $15,960.85 18,833.80$                   31,185.87$                    
HIC Buffer Prep Vessel 3 (V-603)
CBM=Cp0(B1+B2*Fm*Fp) Impeller Diameter (m) 0.625
*vertical for compressors Flat Paddle Power Number 1.8
*L/D= 2.5 to 5 Liquid Density (kg/m^3) 1004
*should be no less than 10 time the liquid volume passing per minute RPS 1.6667
Without Demister
Min Vessel Volume (m3) Pressure (barg) Diameter (m) Power [kW]
3.5 1.52 1.25 0.798 0.3989777
Fp B1 B2
0.795 2.25 1.82
min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $5,932.07
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019




K1 (Table A.1) K2 K3 Cp0
3.8511 0.7009 -0.0003 $6,058.90
Fbm (Table A.7) Cbm CTM CTM 2019
1.38 $8,361.28 9,866.32$                     16,337.10$                    




Table A.40 : HIC Column Costing 
 
 
















90 200,000.00$                
Estimated Price 6/10th Rule
Volume [L] CTM 2003 CTM 2019
650 654,986.73$                1,084,557.03$           
HIC Column (Cl-606)
CBM=Cp0(B1+B2*Fm*Fp) *L/D= 2.5 to 5
*vertical for compressors *should be no less than 10 time the liquid volume passing per minute
Without Demister




min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $3,799.33
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019
SS 20 3.1 $24,319.12 $28,696.57 47,517.09$    
Horizontal Process Vessel
B1 B2
1.49 1.52 min=.3, max = 520 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.5565 0.3776 0.0905 $4,224.72
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019
SS 20 3.1 $20,940.61 24,709.92$                    40,915.82$    




Table A.42 : Diafiltration Flush Tank 3 Costing 
 
 
Table A.43 : Dead-End Filter 4 Costing 
 
 




CBM=Cp0(B1+B2*Fm*Fp) *L/D= 2.5 to 5
*vertical for compressors *should be no less than 10 time the liquid volume passing per minute
Without Demister




min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $4,930.42
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019
SS 20 3.1 $31,559.07 $37,239.71 61,663.21$    
Horizontal Process Vessel
B1 B2
1.49 1.52 min=.3, max = 520 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.5565 0.3776 0.0905 $5,261.30
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019
SS 20 3.1 $26,078.61 30,772.76$                    50,954.94$    
Diafiltration Flush Tank 3 (Tk-609)
CBM=Cp0*Fbm
Area [m^2] SuperPro
70 45,000.00$                
10<P<100 barg
Deadend Plate and Frame Filter Min:0.5 Max:80[m^2]
K1 (Table A.1) K2 K3 Cp0
4.2756 0.352 0.0714 147281.3397
Material Fbm (Table A.7) CBM CTM CTM 2019
SS 1.8 265,106.41$              312,825.57$  517,990.90$                  
Dead-End Fliter 4 (F-412)
$$ Per Unit (14 m^2)
26,417.00$                                 
# of Units $$





Table A.45 : Freezer and cryovessel Costing  
 
 






















Freezer $17,588.24 18 $316,588.32 https://us.vwr.com/store/product/14459968/vwr-ultra-low-temperature-upright-freezers-and-freezer-packages-86-to-50c
Celsius FT100 $125,000.00 http://fedequip.com/inventory/Miscellaneous-Equipment/SARTORIUS-STEDIM-THAW-SYSTEM-MODEL-CELSIUS-FT100.html
https://www.sartoriusglobal.com/_ui/images/h5f/hdc/8880818421790.pdf
CBM=Cp0(B1+B2*Fm*Fp) *L/D= 2.5 to 5
*vertical for compressors *should be no less than 10 time the liquid volume passing per minute
Without Demister




min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $81,302.77
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019
SS 20 3.1 $895,147.34 $1,056,273.86 1,749,026.63$  
Horizontal Process Vessel
B1 B2
1.49 1.52 min=.3, max = 520 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.5565 0.3776 0.0905 $55,747.40
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019
SS 20 3.1 $490,916.22 579,281.14$  959,200.24$     




Table A.47 : Neutralization Vessel Costing 
 
 
Table A.48 :  Potable Water Holding Tank Costing 
 
 
CBM=Cp0(B1+B2*Fm*Fp) Impeller Diameter (m) 0.75
*vertical for compressors Flat Paddle Power Number 1.8
*L/D= 2.5 to 5 Liquid Density (kg/m^3) 995
*should be no less than 10 time the liquid volume passing per minute RPS 1.6667
Without Demister
Min Vessel Volume (m3) Pressure (barg) Diameter (m) Power [kW]
10 2 1.5 1.968 0.983884714
Fp B1 B2
0.921059723 2.25 1.82
min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $11,305.77
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019




K1 (Table A.1) K2 K3 Cp0
3.8511 0.7009 -0.0003 $11,405.66
Fbm (Table A.7) Cbm CTM CTM 2019
1.38 $15,739.82 18,572.98$                   30,754.00$                   
Neutralization Vessel (V-703)
CBM=Cp0(B1+B2*Fm*Fp) *L/D= 2.5 to 5
*vertical for compressors *should be no less than 10 time the liquid volume passing per minute
Without Demister




min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $7,300.61
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019
SS 20 3.1 $46,730.45 $55,141.94 91,306.54$      
Horizontal Process Vessel
B1 B2
1.49 1.52 min=.3, max = 520 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.5565 0.3776 0.0905 $7,322.27
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019
SS 20 3.1 $36,294.16 42,827.10$       70,915.08$      




Table A.49 : Dead-End Filter 4 Costing 
 
 
Table A.50 : Carbon Absorption Column A/B Costing 
 
 










Deadend Plate and Frame Filter Min:0.5 Max:80[m^2]
K1 (Table A.1) K2 K3 Cp0
4.2756 0.352 0.0714 207077.8355
Material Fbm (Table A.7) CBM CTM CTM 2019
SS 1.8 372,740.10$                 439,833.32$                 728,296.16$     
Dead-End Filter 4 (F-803)
CBM=Cp0(B1+B2*Fm*Fp) *L/D= 2.5 to 5
*vertical for compressors *should be no less than 10 time the liquid volume passing per minute
Without Demister




min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $2,355.70
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019
SS 20 3.1 $13,512.19 $15,944.38 52,802.88$      
Carbon Adsorption Column A/B (Cl-804 A/B)
CBM=Cp0(B1+B2*Fm*Fp) *L/D= 2.5 to 5
*vertical for compressors *should be no less than 10 time the liquid volume passing per minute
Without Demister




min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $1,846.32
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019
SS 20 3.1 $11,204.22 $13,220.98 21,891.91$      




Table A.52 : Anion Exchange Column Costing 
 
 
Table A.53 : Ultrafilter Costing 
 
 














CBM=Cp0(B1+B2*Fm*Fp) *L/D= 2.5 to 5
*vertical for compressors *should be no less than 10 time the liquid volume passing per minute
Without Demister




min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $1,723.39
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019
SS 20 3.1 $9,885.27 $11,664.61 19,314.80$      
Anion Exchange Column (Cl-806)
$$ Per Unit (14 m^2)
26,417.00$                                 
# of Units $$




9200 25,295.00$                  
Estimated Price 6/10th Rule
Volume [L] CTM 2019
11000 28,157.73$                  




Table A.55 : Purified Water Tank Costing 
 
 
Table A.56 : Purified Water Pre-Heater Costing 
 
 




CBM=Cp0(B1+B2*Fm*Fp) *L/D= 2.5 to 5
*vertical for compressors *should be no less than 10 time the liquid volume passing per minute
Without Demister




min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $4,930.42
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019
SS 20 3.1 $43,033.71 $50,779.78 84,083.49$       
Horizontal Process Vessel
B1 B2
1.49 1.52 min=.3, max = 520 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.5565 0.3776 0.0905 $5,261.30
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019
SS 20 3.1 $36,304.97 42,839.86$                 70,936.20$       
Purified Water Tank (Tk-809)
CBM=Cp0(B1+B2*Fm*Fp) limits:5-140 barg
Area (m^2) Op Pressure [barg] Design Pressure [barg] C1 C2 C3
0.19471293 62.058 62.058 0.03881 -0.11272 0.08183
limits:10-1000
Fp B1 B2 K1 K2 K3 Cp0
1 1.63 1.66 4.1884 -0.2503 0.1974 29,237.72                     
Heat Exchanger (tube&shell) (U-tube)
Material ID # (Table A.3) Fm (Fig A.18) CBM CTM CTM 2019
SS-shell/SS-Tube 5 2.8 183,554.42        $216,594.22 358,646.63$     
35-70 
Q [Btu/hr] U [Btu/ft^2*hrF] T1 (lnlet tube) T2 (outlet tube) t1 (inlet shell) t2 (outlet shell) DelTlm [F] A (ft^2) A (m^2)
9.63E+03 65 201.9 122 72 76.04 82.18 1.8028975 0.19471293
Purified Water Pre-Heater (HE-811)
CBM=Cp0(B1+B2*Fm*Fp) limits:5-140 barg
Area (m^2) Op Pressure [barg] Design Pressure [barg] C1 C2 C3
17.27315736 62.058 62.058 0.03881 -0.11272 0.08183
limits:10-1000
Fp B1 B2 K1 K2 K3 Cp0
1 1.63 1.66 4.1884 -0.2503 0.1974 15,167.81                     
Heat Exchanger (tube&shell) (U-tube)
Material ID # (Table A.3) Fm (Fig A.18) CBM CTM CTM 2019
SS-shell/SS-Tube 5 2.8 95,223.49          $112,363.72 186,056.99$     
35-70 
Q [Btu/hr] U [Btu/ft^2*hrF] T1 (lnlet tube) T2 (outlet tube) t1 (inlet shell) t2 (outlet shell) DelTlm [F] A (ft^2) A (m^2)





Table A.58 : Steam Boiler Costing 
 
 



















Design Pressure [barg] Duty [kW] Delta T
1.25 231 0
P<20 barg
Steam Boiler Min:1200 Max:9400 [kW] FT: Superheat correction factor for steam boiler
K1 (Table A.1) K2 K3 Cp0 C1 (Table A.2) C2 C3 Fp FT
6.9617 -1.48 0.3161 169628.1786 0 0 0 1.00            1
Tube for nonreactive process heater
Material ID # (Table A.6) Fbm (Fig A.19) CBM CTM CTM 2019
Stainless Steel 55 2.8 474,958.90        560451.5021 928,021.27$     
Steam Boiler (HE-813)
CBM=Cp0*FBM




axial, reciprocating) Min:450 Max:3000 C1,2,3=0 0.95
K1 (Table A.1) K2 K3 Cp0 Choosen CTM
2.2897 1.3604 -0.1027 $30,161.65 554,394.18$     
Centrifugal
Material ID # FBM (A.6/A.19) CBM CTM (2001) CTM 2019
SS 2 6.7 $202,083.04 $238,457.99 394,849.65$     
Axial
Material ID # FBM (A.6/A.19) CBM CTM (2001) CTM 2019
SS 5 8 $241,293.18 $284,725.95 471,462.27$     
Reciprocating
Material ID # FBM (A.6/A.19) CBM CTM (2001) CTM 2019
SS 11 7 $211,131.53 $249,135.21 412,529.49$     
Rotary Min:18 Max:950
K1 (Table A.1) K2 K3 Cp0
5.0355 -1.8002 0.8253 $36,445.98
Material ID # FBM (A.6/A.19) CBM CTM (2001) CTM 2019
SS 8 5 $182,229.90 $215,031.28 356,058.65$     
CBM=Cp0*FBM
Drive
Material ID # (Table A.6) Fbm (Fig A.19) K1 (Table A.1) K2 K3
Electric-totally enclosed 17 3.5 1.956 1.7142 -0.2282
Cp0 CBM limits [kW] CTM CTM 2019





Table A.60 : WFI Storage Tank Costing 
 
 
Table A.61 : Steam Compressor KO Drum Costing 
 
 
CBM=Cp0(B1+B2*Fm*Fp) *L/D= 2.5 to 5
*vertical for compressors *should be no less than 10 time the liquid volume passing per minute
Without Demister




min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $66,680.68
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019
SS 20 3.1 $493,324.74 $582,123.20 963,906.25$     
Horizontal Process Vessel
B1 B2
1.49 1.52 min=.3, max = 520 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.5565 0.3776 0.0905 $47,173.71
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019
SS 20 3.1 $273,121.27 322,283.10$               533,651.11$     
WFI Storage Tank (Tk-817)
CBM=Cp0(B1+B2*Fm*Fp) *L/D= 2.5 to 5
*vertical for compressors *should be no less than 10 time the liquid volume passing per minute
Without Demister




min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $2,613.67
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019
SS 20 3.1 $20,350.32 $24,013.38 39,762.45$       
Horizontal Process Vessel
B1 B2
1.49 1.52 min=.3, max = 520 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.5565 0.3776 0.0905 $3,083.36
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019
SS 20 3.1 $18,850.29 22,243.35$                 36,831.55$       





























CBM=Cp0(B1+B2*Fm*Fp) Impeller Diameter (m) 0.75
*vertical for compressors Flat Paddle Power Number 1.8
*L/D= 2.5 to 5 Liquid Density (kg/m^3) 1004
*should be no less than 10 time the liquid volume passing per minute RPS 1.6667
Without Demister
Min Vessel Volume (m3) Pressure (barg) Diameter (m) Power [kW]
7 1.52 1.5 1.986
Fp B1 B2
0.853570115 2.25 1.82
min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $8,976.99
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019




K1 (Table A.1) K2 K3 Cp0
3.8511 0.7009 -0.0003 $11,477.86
Fbm (Table A.7) Cbm CTM CTM 2019
1.38 $15,839.44 18,690.54$                   30,948.66$                    





























CBM=Cp0(B1+B2*Fm*Fp) Impeller Diameter (m) 1
*vertical for compressors Flat Paddle Power Number 1.8
*L/D= 2.5 to 5 Liquid Density (kg/m^3) 997
*should be no less than 10 time the liquid volume passing per minute RPS 1.6667
Without Demister
Min Vessel Volume (m3) Pressure (barg) Diameter (m) Power [kW]
20 1.52 2 8.309
Fp B1 B2
0.97142682 2.25 1.82
min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $18,310.73
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019




K1 (Table A.1) K2 K3 Cp0
3.8511 0.7009 -0.0003 $31,286.13
Fbm (Table A.7) Cbm CTM CTM 2019
1.38 $43,174.86 50,946.34$                   84,359.28$                    





























CBM=Cp0(B1+B2*Fm*Fp) Impeller Diameter (m) 1.25
*vertical for compressors Flat Paddle Power Number 1.8
*L/D= 2.5 to 5 Liquid Density (kg/m^3) 995
*should be no less than 10 time the liquid volume passing per minute RPS 1.6667
Without Demister
Min Vessel Volume (m3) Pressure (barg) Diameter (m) Power [kW]
30 1.52 2.5 25.306
Fp B1 B2
1.089283526 2.25 1.82
min=.1, max = 628 m3 vessel thickness> .25 in
K1 (Table A.1) K2 K3 Cp0
3.4974 0.4485 0.1074 $24,786.98
Vertical Process Vessel
Material ID # (Table A.3) Fm (Fig A.18) Cbm CTM CTM 2019




K1 (Table A.1) K2 K3 Cp0
3.8511 0.7009 -0.0003 $68,237.76
Fbm (Table A.7) Cbm CTM CTM 2019






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure B.8 : Media Preparation for Bioreactors SuperPro Simulation 
